1
|
Carosella ED. Special Issue: 9th International Conference on HLA-G. Hum Immunol 2023:S0198-8859(23)00088-5. [PMID: 37365070 DOI: 10.1016/j.humimm.2023.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2023]
Affiliation(s)
- Edgardo D Carosella
- Service de Recherche en Hémato-Immunologie, Hôpital Saint Louis APHP, Expert International - Commissariat à l'Energie Atomique (CEA), 75475 Paris Cedex 10, France.
| |
Collapse
|
2
|
Lugand L, Mestrallet G, Laboureur R, Dumont C, Bouhidel F, Djouadou M, Masson-Lecomte A, Desgrandchamps F, Culine S, Carosella ED, Rouas-Freiss N, LeMaoult J. Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies. Front Oncol 2022; 12:898732. [PMID: 35965544 PMCID: PMC9366089 DOI: 10.3389/fonc.2022.898732] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 06/01/2022] [Indexed: 11/25/2022] Open
Abstract
Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with their relative simplicity and handiness have made them the most studied 3D tumor model. Their application as a theranostic tool or as a means to study tumor-host interaction is now well-established in various cancers. However, their use in the field of Renal Cell Carcinoma (RCC) remains very limited. The aim of this work is to present methods to implement a basic RCC spheroid model. These methods cover the steps from RCC tumor dissociation to spheroid infiltration by immune cells. We present a protocol for RCC dissociation using Liberase TM and introduce a culture medium containing Epithelial Growth Factor and Hydrocortisone allowing for faster growth of RCC primary cells. We show that the liquid overlay technique allows for the formation of spheroids from cell lines and from primary cultures. We present a method using morphological criteria to select a homogeneous spheroid population based on a Fiji macro. We then show that spheroids can be infiltrated by PBMCs after activation with OKT3 or IL-15. Finally, we provide an example of application by implementing an immune spheroid killing assay allowing observing increased spheroid destruction after treatment with PD-1 inhibitors. Thus the straightforward methods presented here allow for efficient spheroid formation for a simple RCC 3D model that can be standardized and infused with immune cells to study immunotherapies.
Collapse
Affiliation(s)
- Leonard Lugand
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - Guillaume Mestrallet
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - Rebecca Laboureur
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - Clement Dumont
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
- Department of Medical Oncology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
| | - Fatiha Bouhidel
- Service d’Anatomopathologie Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Laboratory of Pathology, UMR-S728, Paris, France
| | - Malika Djouadou
- Department of Urology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
| | | | - Francois Desgrandchamps
- Department of Urology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
| | - Stephane Culine
- Department of Medical Oncology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
| | - Edgardo D. Carosella
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - Nathalie Rouas-Freiss
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - Joel LeMaoult
- Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France
- *Correspondence: Joel LeMaoult,
| |
Collapse
|
3
|
Dechavanne C, Nouatin O, Adamou R, Edslev S, Hansen A, Meurisse F, Sadissou I, Gbaguidi E, Milet J, Cottrell G, Gineau L, Sabbagh A, Massougbodji A, Moutairou K, Donadi EA, Carosella ED, Moreau P, Remarque E, Theisen M, Rouas-Freiss N, Garcia A, Favier B, Courtin D. Placental Malaria is Associated with Higher LILRB2 Expression in Monocyte Subsets and Lower Anti-Malarial IgG Antibodies During Infancy. Front Immunol 2022; 13:909831. [PMID: 35911674 PMCID: PMC9326509 DOI: 10.3389/fimmu.2022.909831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 06/20/2022] [Indexed: 12/03/2022] Open
Abstract
Background Placental malaria (PM) is associated with a higher susceptibility of infants to Plasmodium falciparum (Pf) malaria. A hypothesis of immune tolerance has been suggested but no clear explanation has been provided so far. Our goal was to investigate the involvement of inhibitory receptors LILRB1 and LILRB2, known to drive immune evasion upon ligation with pathogen and/or host ligands, in PM-induced immune tolerance. Method Infants of women with or without PM were enrolled in Allada, southern Benin, and followed-up for 24 months. Antibodies with specificity for five blood stage parasite antigens were quantified by ELISA, and the frequency of immune cell subsets was quantified by flow cytometry. LILRB1 or LILRB2 expression was assessed on cells collected at 18 and 24 months of age. Findings Infants born to women with PM had a higher risk of developing symptomatic malaria than those born to women without PM (IRR=1.53, p=0.040), and such infants displayed a lower frequency of non-classical monocytes (OR=0.74, p=0.01) that overexpressed LILRB2 (OR=1.36, p=0.002). Moreover, infants born to women with PM had lower levels of cytophilic IgG and higher levels of IL-10 during active infection. Interpretation Modulation of IgG and IL-10 levels could impair monocyte functions (opsonisation/phagocytosis) in infants born to women with PM, possibly contributing to their higher susceptibility to malaria. The long-lasting effect of PM on infants’ monocytes was notable, raising questions about the capacity of ligands such as Rifins or HLA-I molecules to bind to LILRB1 and LILRB2 and to modulate immune responses, and about the reprogramming of neonatal monocytes/macrophages.
Collapse
Affiliation(s)
- Celia Dechavanne
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Odilon Nouatin
- Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Benin
| | - Rafiou Adamou
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
- Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Benin
| | - Sofie Edslev
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | - Anita Hansen
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | - Florian Meurisse
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Ibrahim Sadissou
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
- Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Benin
| | - Erasme Gbaguidi
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
- Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Benin
| | - Jacqueline Milet
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Gilles Cottrell
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Laure Gineau
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Audrey Sabbagh
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Achille Massougbodji
- Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Cotonou, Benin
| | - Kabirou Moutairou
- Laboratoire de Biologie et Physiologie Cellulaires, Faculté des Sciences et Techniques, Université d’Abomey-Calavi, Cotonou, Benin
| | - Eduardo A. Donadi
- Laboratory of Clinical Immunology, Ribeirão Preto Medicine School, University of São Paulo, Ribeirão Preto, Brazil
| | - Edgardo D. Carosella
- CEAA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Philippe Moreau
- CEAA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Ed Remarque
- Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
| | - Michael Theisen
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
- Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
| | - Nathalie Rouas-Freiss
- CEAA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - André Garcia
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
| | - Benoit Favier
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - David Courtin
- UMR 261 MERIT, Université Paris Cité, Institut de Recherche pour le Développement (IRD), Paris, France
- *Correspondence: David Courtin,
| |
Collapse
|
4
|
Mestrallet G, Carosella ED, Martin MT, Rouas-Freiss N, Fortunel NO, LeMaoult J. Immunosuppressive Properties of Epidermal Keratinocytes Differ According to Their Immaturity Status. Front Immunol 2022; 13:786859. [PMID: 35222373 PMCID: PMC8878806 DOI: 10.3389/fimmu.2022.786859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 01/14/2022] [Indexed: 12/04/2022] Open
Abstract
Preservation of a functional keratinocyte stem cell pool is essential to ensure the long-term maintenance of epidermis integrity, through continuous physiological renewal and regeneration in case of injury. Protecting stem cells from inflammation and immune reactions is thus a critical issue that needs to be explored. Here, we show that the immature CD49fhigh precursor cell fraction from interfollicular epidermis keratinocytes, comprising stem cells and progenitors, is able to inhibit CD4+ T-cell proliferation. Of note, both the stem cell-enriched CD49fhigh/EGFRlow subpopulation and the less immature CD49fhigh/EGFRhigh progenitors ensure this effect. Moreover, we show that HLA-G and PD-L1 immune checkpoints are overexpressed in CD49fhigh precursors, as compared to CD49flow differentiated keratinocytes. This potency may limit immune reactions against immature precursors including stem cells, and protect them from exacerbated inflammation. Further exploring this correlation between immuno-modulation and immaturity may open perspectives in allogenic cell therapies.
Collapse
Affiliation(s)
- Guillaume Mestrallet
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Evry, France
- Université Paris-Saclay, Saint-Aubin, France
| | - Edgardo D. Carosella
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Michele T. Martin
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Evry, France
- Université Paris-Saclay, Saint-Aubin, France
| | - Nathalie Rouas-Freiss
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Nicolas O. Fortunel
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Evry, France
- Université Paris-Saclay, Saint-Aubin, France
- *Correspondence: Joel LeMaoult, ; Nicolas O. Fortunel,
| | - Joel LeMaoult
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, IRSL, Université Paris, Paris, France
- *Correspondence: Joel LeMaoult, ; Nicolas O. Fortunel,
| |
Collapse
|
5
|
Palma MB, Tronik-Le Roux D, Amín G, Castañeda S, Möbbs AM, Scarafia MA, La Greca A, Daouya M, Poras I, Inda AM, Moro LN, Carosella ED, García MN, Miriuka SG. HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy. Sci Rep 2021; 11:22158. [PMID: 34773056 PMCID: PMC8589947 DOI: 10.1038/s41598-021-01572-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 10/22/2021] [Indexed: 11/08/2022] Open
Abstract
Cancer immunotherapies based mainly on the blockade of immune-checkpoint (IC) molecules by anti-IC antibodies offer new alternatives for treatment in oncological diseases. However, a considerable proportion of patients remain unresponsive to them. Hence, the development of novel clinical immunotherapeutic approaches and/or targets are crucial.W In this context, targeting the immune-checkpoint HLA-G/ILT2/ILT4 has caused great interest since it is abnormally expressed in several malignancies generating a tolerogenic microenvironment. Here, we used CRISPR/Cas9 gene editing to block the HLA-G expression in two tumor cell lines expressing HLA-G, including a renal cell carcinoma (RCC7) and a choriocarcinoma (JEG-3). Different sgRNA/Cas9 plasmids targeting HLA-G exon 1 and 2 were transfected in both cell lines. Downregulation of HLA-G was reached to different degrees, including complete silencing. Most importantly, HLA-G - cells triggered a higher in vitro response of immune cells with respect to HLA-G + wild type cells. Altogether, we demonstrated for the first time the HLA-G downregulation through gene editing. We propose this approach as a first step to develop novel clinical immunotherapeutic approaches in cancer.
Collapse
Affiliation(s)
- María Belén Palma
- Cátedra de Citología, Histología y Embriología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina
- LIAN-CONICET, Fundación FLENI, Buenos Aires, Argentina
| | - Diana Tronik-Le Roux
- Atomic Energy and Alternative Energies Agency (CEA), Hematology and Immunology Research Division, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, University of Paris, Paris, France
| | | | | | - Alan M Möbbs
- LIAN-CONICET, Fundación FLENI, Buenos Aires, Argentina
| | | | | | - Marina Daouya
- Atomic Energy and Alternative Energies Agency (CEA), Hematology and Immunology Research Division, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, University of Paris, Paris, France
| | - Isabelle Poras
- Atomic Energy and Alternative Energies Agency (CEA), Hematology and Immunology Research Division, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, University of Paris, Paris, France
| | - Ana María Inda
- Cátedra de Citología, Histología y Embriología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina
- Comisión de Investigaciones Científicas (CIC), Buenos Aires, Argentina
| | - Lucía N Moro
- LIAN-CONICET, Fundación FLENI, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Edgardo D Carosella
- Atomic Energy and Alternative Energies Agency (CEA), Hematology and Immunology Research Division, Saint-Louis Hospital, Paris, France
- U976 HIPI Unit, University of Paris, Paris, France
| | - Marcela N García
- Cátedra de Citología, Histología y Embriología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina.
| | - Santiago G Miriuka
- LIAN-CONICET, Fundación FLENI, Buenos Aires, Argentina.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
| |
Collapse
|
6
|
Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Spadaro S, Strazzabosco G, Campo G, Carosella ED, Papi A, Rizzo R, Contoli M. Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion. Viruses 2021; 13:v13091855. [PMID: 34578436 PMCID: PMC8473385 DOI: 10.3390/v13091855] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 09/12/2021] [Accepted: 09/14/2021] [Indexed: 12/17/2022] Open
Abstract
Human leukocyte antigen (HLA) is a group of molecules involved in inflammatory and infective responses. We evaluated blood sHLA-E and sHLA-G levels in hospitalized COVID-19 patients with respiratory failure and their relationship with clinical evolution, changes in endothelial activation biomarker profile, and neutrophil adhesion. sHLA-E, sHLA-G, and endothelial activation biomarkers were quantified by ELISA assay in plasma samples. Neutrophil adhesion to endothelium was assessed in the presence/absence of patients’ plasma samples. At admission, plasma levels of sHLA-G and sHLA-E were significantly higher in COVID-19 patients with respiratory failure compared to controls. COVID-19 clinical improvement was associated with increased sHLA-G plasma levels. In COVID-19, but not in control patients, an inverse correlation was found between serum sICAM-1 and E-selectin levels and plasma sHLA-G values. The in vitro analysis of activated endothelial cells confirmed the ability of HLA-G molecules to control sICAM-1 and sE-selectin expression via CD160 interaction and FGF2 induction and consequently neutrophil adhesion. We suggest a potential role for sHLA-G in improving COVID-19 patients’ clinical condition related to the control of neutrophil adhesion to activated endothelium.
Collapse
Affiliation(s)
- Daria Bortolotti
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Valentina Gentili
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Sabrina Rizzo
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Giovanna Schiuma
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Silvia Beltrami
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Savino Spadaro
- Intensive Care Unit, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy;
| | - Giovanni Strazzabosco
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
| | - Gianluca Campo
- Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, 44124 Ferrara, Italy;
| | - Edgardo D. Carosella
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 75001 Paris, France;
| | - Alberto Papi
- Respiratory Section, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; (A.P.); (M.C.)
- Respiratory Unit, Azienda Ospedaliera Universitaria Ferrara, Cona, 44124 Ferrara, Italy
| | - Roberta Rizzo
- Department of Chemical, Pharmaceutical and Agricultural Science, University of Ferrara, 44121 Ferrara, Italy; (D.B.); (V.G.); (S.R.); (G.S.); (S.B.); (G.S.)
- Industrial Research and Technology Transfer Laboratory (LTTA), University of Ferrara, 44121 Ferrara, Italy
- Correspondence: ; Tel.: +39-0532455382
| | - Marco Contoli
- Respiratory Section, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; (A.P.); (M.C.)
- Respiratory Unit, Azienda Ospedaliera Universitaria Ferrara, Cona, 44124 Ferrara, Italy
| |
Collapse
|
7
|
Mestrallet G, Auvré F, Schenowitz C, Carosella ED, LeMaoult J, Martin MT, Rouas-Freiss N, Fortunel NO. Human Keratinocytes Inhibit CD4 + T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints. Cells 2021; 10:cells10061438. [PMID: 34201301 PMCID: PMC8227977 DOI: 10.3390/cells10061438] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/03/2021] [Accepted: 06/04/2021] [Indexed: 01/18/2023] Open
Abstract
Human skin protects the body against infection and injury. This protection involves immune and epithelial cells, but their interactions remain largely unknown. Here, we show that cultured epidermal keratinocytes inhibit allogenic CD4+ T-cell proliferation under both normal and inflammatory conditions. Inhibition occurs through the secretion of soluble factors, including TGFB1 and the cell-surface expression of HLA-G1 and PD-L1 immune checkpoints. For the first time, we here describe the expression of the HLA-G1 protein in healthy human skin and its role in keratinocyte-driven tissue immunomodulation. The overexpression of HLA-G1 with an inducible vector increased the immunosuppressive properties of keratinocytes, opening up perspectives for their use in allogeneic settings for cell therapy.
Collapse
Affiliation(s)
- Guillaume Mestrallet
- CEA, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Francois Jacob Institute of Biology, DRF, 91000 Evry, France; (G.M.); (F.A.)
- Université Paris-Saclay, 91190 Saint-Aubin, France
| | - Frédéric Auvré
- CEA, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Francois Jacob Institute of Biology, DRF, 91000 Evry, France; (G.M.); (F.A.)
- Université Paris-Saclay, 91190 Saint-Aubin, France
| | - Chantal Schenowitz
- CEA, DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, 75010 Paris, France; (C.S.); (E.D.C.)
- U976 HIPI Unit, IRSL, Université Paris, 75010 Paris, France
| | - Edgardo D. Carosella
- CEA, DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, 75010 Paris, France; (C.S.); (E.D.C.)
- U976 HIPI Unit, IRSL, Université Paris, 75010 Paris, France
| | - Joel LeMaoult
- CEA, DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, 75010 Paris, France; (C.S.); (E.D.C.)
- U976 HIPI Unit, IRSL, Université Paris, 75010 Paris, France
- Correspondence: (J.L.); (M.T.M.); (N.R.-F.); (N.O.F.); Tel.: +33-1-60-87-34-91 (M.T.M.); +33-1-57-27-68-01 (N.R.-F.); +33-1-60-87-34-92 (N.O.F.)
| | - Michèle T. Martin
- CEA, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Francois Jacob Institute of Biology, DRF, 91000 Evry, France; (G.M.); (F.A.)
- Université Paris-Saclay, 91190 Saint-Aubin, France
- Correspondence: (J.L.); (M.T.M.); (N.R.-F.); (N.O.F.); Tel.: +33-1-60-87-34-91 (M.T.M.); +33-1-57-27-68-01 (N.R.-F.); +33-1-60-87-34-92 (N.O.F.)
| | - Nathalie Rouas-Freiss
- CEA, DRF, Francois Jacob Institute of Biology, Hemato-Immunology Research Department, Saint-Louis Hospital, 75010 Paris, France; (C.S.); (E.D.C.)
- U976 HIPI Unit, IRSL, Université Paris, 75010 Paris, France
- Correspondence: (J.L.); (M.T.M.); (N.R.-F.); (N.O.F.); Tel.: +33-1-60-87-34-91 (M.T.M.); +33-1-57-27-68-01 (N.R.-F.); +33-1-60-87-34-92 (N.O.F.)
| | - Nicolas O. Fortunel
- CEA, Laboratory of Genomics and Radiobiology of Keratinopoiesis, Institute of Cellular and Molecular Radiobiology, Francois Jacob Institute of Biology, DRF, 91000 Evry, France; (G.M.); (F.A.)
- Université Paris-Saclay, 91190 Saint-Aubin, France
- Correspondence: (J.L.); (M.T.M.); (N.R.-F.); (N.O.F.); Tel.: +33-1-60-87-34-91 (M.T.M.); +33-1-57-27-68-01 (N.R.-F.); +33-1-60-87-34-92 (N.O.F.)
| |
Collapse
|
8
|
Rouas-Freiss N, Moreau P, LeMaoult J, Papp B, Tronik-Le Roux D, Carosella ED. Role of the HLA-G immune checkpoint molecule in pregnancy. Hum Immunol 2021; 82:353-361. [PMID: 33745758 DOI: 10.1016/j.humimm.2021.01.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 12/22/2020] [Accepted: 01/05/2021] [Indexed: 12/21/2022]
Abstract
The non-classical HLA class I molecule HLA-G is expressed in trophoblasts where it contributes to maternal-fetal tolerance. HLA-G has been implicated in the control of trophoblast invasion, uterine vascular remodeling, and maintenance of a local immunosuppressive state. Understanding HLA-G biology at the maternal-fetal interface is therefore a critical issue in reproduction. In this regard, we review here: (i) the effects of HLA-G on decidual leucocytes and stromal cells, (ii) the contribution of trogocytosis in HLA-G expression on decidual cells, (iii) its interaction with the ILT2, ILT4 and KIR2DL4 receptors, (iv) the link between HLA-G polymorphism and pregnancy disorders, and (v) the expression of newly-described HLA-G isoforms at the maternal-fetal interface.
Collapse
Affiliation(s)
- Nathalie Rouas-Freiss
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Philippe Moreau
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Joel LeMaoult
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Bela Papp
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Diana Tronik-Le Roux
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France
| | - Edgardo D Carosella
- CEA, DRF-Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France; U976 HIPI Unit, IRSL, Université Paris, Paris, France.
| |
Collapse
|
9
|
Schwich E, Hò GGT, LeMaoult J, Bade-Döding C, Carosella ED, Horn PA, Rebmann V. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary. Front Immunol 2020; 11:2046. [PMID: 32973812 PMCID: PMC7472666 DOI: 10.3389/fimmu.2020.02046] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/28/2020] [Indexed: 12/23/2022] Open
Abstract
Tumor immune escape is associated with both, the expression of immune checkpoint molecules on peripheral immune cells and soluble forms of the human leukocyte antigen-G (HLA-G) in the blood, which are consequently discussed as clinical biomarker for disease status and outcome of cancer patients. HLA-G preferentially interacts with the inhibitory receptor immunoglobulin-like transcript (ILT) receptor-2 in the blood and can be secreted as free soluble molecules (sHLA-G) or via extracellular vesicles (EV). To investigate the contribution of these two forms to the expression of checkpoint molecules in peripheral blood, we primed peripheral blood mononuclear cells with purified soluble sHLA-G1 protein, or EV preparations derived from SUM149 cells transfected with membrane-bound HLA-G1 or control vector prior to anti-CD3/CD28 T cell activation. Our study demonstrated that priming of PBMC with sHLA-G1 protein prior to 48 h activation resulted in enhanced frequencies of ILT-2 expressing CD8+ T cells, and in an upregulation of immune checkpoint molecules CTLA-4, PD-1, TIM-3, and CD95 exclusively on ILT-2 positive CD8+ T cells. In contrast, when PBMC were primed with EV (containing HLA-G1 or not) upregulation of CTLA-4, PD-1, TIM-3, and CD95 occurred exclusively on ILT-2 negative CD8+ T cells. Taken together, our data suggest that priming with sHLA-G forms induces a pronounced immunosuppressive/exhausted phenotype and that priming with sHLA-G1 protein or EV derived from HLA-G1 positive or negative SUM149 cells affects CD8+ T cells complementary by targeting either the ILT-2 positive or negative subpopulation, respectively, after T cell activation.
Collapse
Affiliation(s)
- Esther Schwich
- Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Gia-Gia T Hò
- Institute for Transfusion Medicine, Hannover Medical School, Hanover, Germany
| | - Joel LeMaoult
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Université de paris, Paris, France
| | | | - Edgardo D Carosella
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Université de paris, Paris, France
| | - Peter A Horn
- Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Vera Rebmann
- Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
10
|
García M, Palma MB, Verine J, Miriuka S, Inda AM, Errecalde AL, Desgrandchamps F, Carosella ED, Tronik-Le Roux D. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma. BMC Cancer 2020; 20:624. [PMID: 32620162 PMCID: PMC7333411 DOI: 10.1186/s12885-020-07113-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 06/25/2020] [Indexed: 12/19/2022] Open
Abstract
Background Clear cell renal cell carcinoma (ccRCC), the most aggressive renal cancer, is characterized by early lymph node metastases and bad prognosis. Most therapies targeting advanced or metastatic ccRCC are based, as first-line treatment, on the administration of the vascular endothelial growth factor (VEGF) neutralizing antibody termed Bevacizumab. Despite proven benefits, the expected results were not obtained for the majority of patients. The possibility that an intricate interplay between angiogenesis and immune-checkpoints might exist lead us to evaluate tumor angiogenesis, by means of VEGF expression together with the immune checkpoint HLA-G/ILT4. Methods Tumor specimens were obtained from patients from two separate cohorts: One from “Evita Pueblo” Hospital from Berazategui, (Buenos Aires, Argentina) and the second includes patients surgically operated at the Urology Department of Saint-Louis Hospital (Paris, France) with a confirmed ccRCC diagnosis. Immunohistochemistry was performed with specific antibodies directed against HLA-G, VEGF-A, VEGF-C, D240, CD34, ILT4 and Ca-IX. In addition, gene expression levels were measured in a cell line derived from a ccRCC patient by semi-quantitative RT-PCR. Results Our results show that the highly vascularized tumors of ccRCC patients express high levels of VEGF and the immune-checkpoint HLA-G. In addition, ILT4, one of the HLA-G receptors, was detected on macrophages surrounding tumor cells, suggesting the generation of an immune-tolerant microenvironment that might favor tumorigenesis. Notably, RT-qPCR analysis provided the first evidence on the transcriptional relationship between HLA-G/ILT4 and the VEGF family. Namely, in the presence of HLA-G or ILT4, the levels of VEGF-A are diminished whereas those of VEGF-C are increased. Conclusions In an effort to find new therapeutic molecules and fight against metastasis dissemination associated with the poor survival rates of ccRCC patients, these findings provide the rationale for co-targeting angiogenesis and the immune checkpoint HLA-G.
Collapse
Affiliation(s)
- Marcela García
- Chair of Cytology, Histology and Embryology, Faculty of Medical Sciences, UNLP, Buenos Aires, Argentina
| | - Maria Belen Palma
- Chair of Cytology, Histology and Embryology, Faculty of Medical Sciences, UNLP, Buenos Aires, Argentina.,LIAN, FLENI-CONICET, Escobar, Argentina
| | - Jerome Verine
- AP-HP, Saint-Louis Hospital, Department of Pathology, Paris, France.,CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Santiago Miriuka
- Chair of Cytology, Histology and Embryology, Faculty of Medical Sciences, UNLP, Buenos Aires, Argentina.,LIAN, FLENI-CONICET, Escobar, Argentina
| | - Ana M Inda
- Chair of Cytology, Histology and Embryology, Faculty of Medical Sciences, UNLP, Buenos Aires, Argentina.,CIC, Pcia, de Buenos Aires, Argentina
| | - Ana L Errecalde
- Chair of Cytology, Histology and Embryology, Faculty of Medical Sciences, UNLP, Buenos Aires, Argentina
| | - François Desgrandchamps
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France.,AP-HP, Department of Urology, Saint-Louis Hospital, Paris, France
| | - Edgardo D Carosella
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France.,University of Paris, IRSL, UMRS 976, Paris, France
| | - Diana Tronik-Le Roux
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France. .,University of Paris, IRSL, UMRS 976, Paris, France.
| |
Collapse
|
11
|
Papp B, Launay S, Gélébart P, Arbabian A, Enyedi A, Brouland JP, Carosella ED, Adle-Biassette H. Endoplasmic Reticulum Calcium Pumps and Tumor Cell Differentiation. Int J Mol Sci 2020; 21:ijms21093351. [PMID: 32397400 PMCID: PMC7247589 DOI: 10.3390/ijms21093351] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 05/01/2020] [Accepted: 05/02/2020] [Indexed: 12/21/2022] Open
Abstract
Endoplasmic reticulum (ER) calcium homeostasis plays an essential role in cellular calcium signaling, intra-ER protein chaperoning and maturation, as well as in the interaction of the ER with other organelles. Calcium is accumulated in the ER by sarco/endoplasmic reticulum calcium ATPases (SERCA enzymes) that generate by active, ATP-dependent transport, a several thousand-fold calcium ion concentration gradient between the cytosol (low nanomolar) and the ER lumen (high micromolar). SERCA enzymes are coded by three genes that by alternative splicing give rise to several isoforms, which can display isoform-specific calcium transport characteristics. SERCA expression levels and isoenzyme composition vary according to cell type, and this constitutes a mechanism whereby ER calcium homeostasis is adapted to the signaling and metabolic needs of the cell, depending on its phenotype, its state of activation and differentiation. As reviewed here, in several normal epithelial cell types including bronchial, mammary, gastric, colonic and choroid plexus epithelium, as well as in mature cells of hematopoietic origin such as pumps are simultaneously expressed, whereas in corresponding tumors and leukemias SERCA3 expression is selectively down-regulated. SERCA3 expression is restored during the pharmacologically induced differentiation of various cancer and leukemia cell types. SERCA3 is a useful marker for the study of cell differentiation, and the loss of SERCA3 expression constitutes a previously unrecognized example of the remodeling of calcium homeostasis in tumors.
Collapse
Affiliation(s)
- Bela Papp
- Institut National de la Santé et de la Recherche Médicale, UMR U976, Institut Saint-Louis, 75010 Paris, France
- Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Université de Paris, 75010 Paris, France
- CEA, DRF-Institut Francois Jacob, Department of Hemato-Immunology Research, Hôpital Saint-Louis, 75010 Paris, France;
- Correspondence: or
| | - Sophie Launay
- EA481, UFR Santé, Université de Bourgogne Franche-Comté, 25000 Besançon, France;
| | - Pascal Gélébart
- Department of Clinical Science-Hematology Section, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway;
| | - Atousa Arbabian
- Laboratoire d’Innovation Vaccins, Institut Pasteur de Paris, 75015 Paris, France;
| | - Agnes Enyedi
- Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary;
| | - Jean-Philippe Brouland
- Institut Universitaire de Pathologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland;
| | - Edgardo D. Carosella
- CEA, DRF-Institut Francois Jacob, Department of Hemato-Immunology Research, Hôpital Saint-Louis, 75010 Paris, France;
| | - Homa Adle-Biassette
- AP-HP, Service d’Anatomie et Cytologie Pathologiques, Hôpital Lariboisière, 75010 Paris, France;
- Université de Paris, NeuroDiderot, Inserm UMR 1141, 75019 Paris, France
| |
Collapse
|
12
|
Proust R, Ponsen AC, Rouffiac V, Schenowitz C, Montespan F, Ser-Le Roux K, De Leeuw F, Laplace-Builhé C, Mauduit P, Carosella ED, Banzet S, Lataillade JJ, Rouas-Freiss N, Uzan G, Peltzer J. Cord blood-endothelial colony forming cells are immunotolerated and participate at post-ischemic angiogenesis in an original dorsal chamber immunocompetent mouse model. Stem Cell Res Ther 2020; 11:172. [PMID: 32381102 PMCID: PMC7206734 DOI: 10.1186/s13287-020-01687-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Revised: 03/30/2020] [Accepted: 04/22/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Cardiovascular diseases are the main cause of morbidity and mortality worldwide. Restoring blood supply to ischemic tissues is an essential goal for the successful treatment of these diseases. Growth factor or gene therapy efficacy remains controversial, but stem cell transplantation is emerging as an interesting approach to stimulate angiogenesis. Among the different stem cell populations, cord blood-endothelial progenitor cells (CB-EPCs) and more particularly cord blood-endothelial progenitor cell-derived endothelial colony forming cells (CB-ECFCs) have a great proliferative potential without exhibiting signs of senescence. Even if it was already described that CB-ECFCs were able to restore blood perfusion in hind-limb ischemia in an immunodeficient mouse model, until now, the immunogenic potential of allogenic CB-ECFCs remains controversial. Therefore, our objectives were to evaluate the immune tolerance potency of CB-ECFCs and their capacity to restore a functional vascular network under ischemic condition in immunocompetent mice. METHODS In vitro, the expression and secretion of immunoregulatory markers (HLA-G, IL-10, and TGF-β1) were evaluated on CB-ECFCs. Moreover, CB-ECFCs were co-cultured with activated peripheral blood mononuclear cells (PBMCs) for 6 days. PBMC proliferation was evaluated by [3H]-thymidine incorporation on the last 18 h. In vivo, CB-ECFCs were administered in the spleen and muscle of immunocompetent mice. Tissues were collected at day 14 after surgery. Finally, CB-ECFCs were injected intradermally in C57BL/6JRj mice close to ischemic macrovessel induced by thermal cauterization. Mice recovered until day 5 and were imaged, twice a week until day 30. RESULTS Firstly, we demonstrated that CB-ECFCs expressed HLA-G, IL-10, and TGF-β1 and secreted IL-10 and TGF-β1 and that they could display immunosuppressive properties in vitro. Secondly, we showed that CB-ECFCs could be tolerated until 14 days in immunocompetent mice. Thirdly, we revealed in an original ischemic model of dorsal chamber that CB-ECFCs were integrated in a new functional vascular network. CONCLUSION These results open up new perspectives about using CB-ECFCs as an allogeneic cell therapy product and gives new impulse to the treatment of cardiovascular diseases.
Collapse
Affiliation(s)
- Richard Proust
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Anne-Charlotte Ponsen
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Valérie Rouffiac
- Paris-Saclay University, Paris-Sud University, Gustave Roussy Institute, INSERM, CNRS, Molecular Analysis, Modeling and Imaging of Cancer Disease, Villejuif, France
| | - Chantal Schenowitz
- CEA, DRF-IBFJ, Hemato-Immunology Research Unit, INSERM UMR-S 976, IRSL - Paris University, Saint-Louis Hospital, Paris, France
| | - Florent Montespan
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Karine Ser-Le Roux
- Paris-Saclay University, Paris-Sud University, Gustave Roussy Institute, INSERM, CNRS, Molecular Analysis, Modeling and Imaging of Cancer Disease, Villejuif, France
| | - Frédéric De Leeuw
- Paris-Saclay University, Paris-Sud University, Gustave Roussy Institute, INSERM, CNRS, Molecular Analysis, Modeling and Imaging of Cancer Disease, Villejuif, France
| | - Corinne Laplace-Builhé
- Paris-Saclay University, Paris-Sud University, Gustave Roussy Institute, INSERM, CNRS, Molecular Analysis, Modeling and Imaging of Cancer Disease, Villejuif, France
| | - Philippe Mauduit
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Edgardo D Carosella
- CEA, DRF-IBFJ, Hemato-Immunology Research Unit, INSERM UMR-S 976, IRSL - Paris University, Saint-Louis Hospital, Paris, France
| | - Sébastien Banzet
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Jean-Jacques Lataillade
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Nathalie Rouas-Freiss
- CEA, DRF-IBFJ, Hemato-Immunology Research Unit, INSERM UMR-S 976, IRSL - Paris University, Saint-Louis Hospital, Paris, France
| | - Georges Uzan
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France
| | - Juliette Peltzer
- INSERM UMR-S-MD 1197/Ministry of the Armed Forces, Biomedical Research Institut of the Armed Forces (IRBA), Paul-Brousse Hospital Villejuif and CTSA Clamart, Clamart, France.
| |
Collapse
|
13
|
Tronik-Le Roux D, Sautreuil M, Bentriou M, Vérine J, Palma MB, Daouya M, Bouhidel F, Lemler S, LeMaoult J, Desgrandchamps F, Cournède PH, Carosella ED. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets. Cancer Immunol Immunother 2020; 69:1237-1252. [PMID: 32166404 DOI: 10.1007/s00262-020-02530-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 02/18/2020] [Indexed: 12/18/2022]
Abstract
Clear cell renal cell carcinoma (ccRCC) constitutes the most common renal cell carcinoma subtype and has long been recognized as an immunogenic cancer. As such, significant attention has been directed toward optimizing immune-checkpoints (IC)-based therapies. Despite proven benefits, a substantial number of patients remain unresponsive to treatment, suggesting that yet unreported, immunosuppressive mechanisms coexist within tumors and their microenvironment. Here, we comprehensively analyzed and ranked forty-four immune-checkpoints expressed in ccRCC on the basis of in-depth analysis of RNAseq data collected from the TCGA database and advanced statistical methods designed to obtain the group of checkpoints that best discriminates tumor from healthy tissues. Immunohistochemistry and flow cytometry confirmed and enlarged the bioinformatics results. In particular, by using the recursive feature elimination method, we show that HLA-G, B7H3, PDL-1 and ILT2 are the most relevant genes that characterize ccRCC. Notably, ILT2 expression was detected for the first time on tumor cells. The levels of other ligand-receptor pairs such as CD70:CD27; 4-1BB:4-1BBL; CD40:CD40L; CD86:CTLA4; MHC-II:Lag3; CD200:CD200R; CD244:CD48 were also found highly expressed in tumors compared to adjacent non-tumor tissues. Collectively, our approach provides a comprehensible classification of forty-four IC expressed in ccRCC, some of which were never reported before to be co-expressed in ccRCC. In addition, the algorithms used allowed identifying the most relevant group that best discriminates tumor from healthy tissues. The data can potentially assist on the choice of valuable immune-therapy targets which hold potential for the development of more effective anti-tumor treatments.
Collapse
Affiliation(s)
- Diana Tronik-Le Roux
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France. .,Université de paris, U976 HIPI Unit, Institut de Recherche Saint-Louis, 75010, Paris, France. .,CEA, Direction de La Recherche Fondamentale, Service de Recherche en Hémato-Immunologie, Hôpital Saint-Louis, IUH, 1, avenue Claude Vellefaux, 75010, Paris, France.
| | - Mathilde Sautreuil
- Laboratory of Mathematics and Informatics (MICS), CentraleSupélec, Université Paris-Saclay, 91190, Gif-sur-Yvette, France
| | - Mahmoud Bentriou
- Laboratory of Mathematics and Informatics (MICS), CentraleSupélec, Université Paris-Saclay, 91190, Gif-sur-Yvette, France
| | - Jérôme Vérine
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Service D'Anatomo-Pathologie, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Maria Belén Palma
- Cátedra de Citología, Histología Y Embriología A, Facultad de Ciencias Médicas, UNLP, Buenos Aires, Argentina
| | - Marina Daouya
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Université de paris, U976 HIPI Unit, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Fatiha Bouhidel
- Service D'Anatomo-Pathologie, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Sarah Lemler
- Laboratory of Mathematics and Informatics (MICS), CentraleSupélec, Université Paris-Saclay, 91190, Gif-sur-Yvette, France
| | - Joel LeMaoult
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Université de paris, U976 HIPI Unit, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - François Desgrandchamps
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Service D'Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Paul-Henry Cournède
- Laboratory of Mathematics and Informatics (MICS), CentraleSupélec, Université Paris-Saclay, 91190, Gif-sur-Yvette, France
| | - Edgardo D Carosella
- Commissariat à L'Energie Atomique Et Aux Energies Alternatives (CEA), Direction de La Recherche Fondamentale (DRF), Service de Recherche en Hémato-Immunologie (SRHI), Hôpital Saint-Louis, Paris, France.,Université de paris, U976 HIPI Unit, Institut de Recherche Saint-Louis, 75010, Paris, France
| |
Collapse
|
14
|
Jacquier A, Dumont C, Carosella ED, Rouas-Freiss N, LeMaoult J. Cytometry-based analysis of HLA-G functions according to ILT2 expression. Hum Immunol 2020; 81:168-177. [PMID: 32081570 DOI: 10.1016/j.humimm.2020.02.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 01/17/2020] [Accepted: 02/03/2020] [Indexed: 01/14/2023]
Abstract
HLA-G was described as a molecule inhibiting NK and T cells functions through its receptor, ILT2. However, most functional studies of HLA-G were so far performed on heterogeneous immune populations and regardless of ILT2 expression. This may lead to an underestimation of the effect of HLA-G. Thus, considering the immune subpopulations sensitive to HLA-G remained an important issue in the field. Here we present a new cytometry assay to evaluate HLA-G effects on both NK and CD8+ T cell cytotoxic functions. Using flow cytometry allows for the comparison of HLA-G function on multiple subsets and multiple functions in the same time. In particular, we sharpen the analysis by specifically studying the immune subpopulations expressing HLA-G receptor ILT2. We focused our work on: IFN-gamma production and cytotoxicity (CD107a expression) by CD8+ T cells and NK cells expressing or not ILT2. We compared the expression of these markers in presence of target cells, expressing or not HLA-G1, and added a blocking antibody to reverse HLA-G inhibition. This new method allows for the discrimination of cell subsets responding and non-responding to HLA-G1 in one tube. We confirm that HLA-G-specifically inhibits the ILT2+ CD8+ T cell and ILT2+ NK cell subsets but not ILT2-negative ones. By blocking HLA-G/ILT2 interaction using an anti-ILT2 antibody we restored the cytotoxicity level, corroborating the specific inhibition of HLA-G1. We believe that our methodology enables to investigate HLA-G immune functions easily and finely towards other immune cell lineages or expressing other receptors, and might be applied in several pathological contexts, such as cancer and transplantation.
Collapse
Affiliation(s)
- A Jacquier
- CEA, DRF-Francois Jacob Institute, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France; U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - C Dumont
- Department of Medical Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France
| | - E D Carosella
- CEA, DRF-Francois Jacob Institute, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France; U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - N Rouas-Freiss
- CEA, DRF-Francois Jacob Institute, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France; U976 HIPI Unit, IRSL, Paris University, Paris, France
| | - J LeMaoult
- CEA, DRF-Francois Jacob Institute, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France; U976 HIPI Unit, IRSL, Paris University, Paris, France.
| |
Collapse
|
15
|
Voisin C, Cauchois G, Reppel L, Laroye C, Louarn L, Schenowitz C, Sonon P, Poras I, Wang V, D. Carosella E, Benkirane-Jessel N, Moreau P, Rouas-Freiss N, Bensoussan D, Huselstein C. Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation? J Clin Med 2020; 9:jcm9020423. [PMID: 32033151 PMCID: PMC7073626 DOI: 10.3390/jcm9020423] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 01/24/2020] [Accepted: 01/28/2020] [Indexed: 01/13/2023] Open
Abstract
Background: Umbilical mesenchymal stem/stromal cells (MSCs), and especially those derived from Wharton’s jelly (WJ), are a promising engineering tool for tissue repair in an allogeneic context. This is due to their differentiation capacity and immunological properties, like their immunomodulatory potential and paracrine activity. Hence, these cells may be considered an Advanced Therapy Medicinal Product (ATMP). The purpose of this work was to differentiate MSCs from WJ (WJ-MSCs) into chondrocytes using a scaffold and to evaluate, in vitro, the immunomodulatory capacities of WJ-MSCs in an allogeneic and inflammatory context, mimicked by IFN-γ and TNF-α priming during the chondrogenic differentiation. Methods: Scaffolds were made from hydrogel composed by alginate enriched in hyaluronic acid (Alg/HA). Chondrogenic differentiation, immunological function, phenotype expression, but also secreted soluble factors were the different parameters followed during 28 days of culture. Results: During chondrocyte differentiation, even in an allogeneic context, WJ-MSCs remained unable to establish the immunological synapse or to induce T cell alloproliferation. Moreover, interestingly, paracrine activity and functional immunomodulation were maintained during cell differentiation. Conclusion: These results show that WJ-MSCs remained hypoimmunogenic and retained immunomodulatory properties even when they had undergone chondrocyte differentiation.
Collapse
Affiliation(s)
- Charlotte Voisin
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- Correspondence: ; Tel.: +33-372-74-6585
| | - Ghislaine Cauchois
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| | - Loïc Reppel
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Caroline Laroye
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Laetitia Louarn
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Chantal Schenowitz
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Paulin Sonon
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Isabelle Poras
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Valentine Wang
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| | - Edgardo D. Carosella
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Nadia Benkirane-Jessel
- INSERM-UNISTRA UMR1260, Regenerative Nanomedicine laboratory, Faculté de Médecine, FMTS, Strasbourg CEDEX F-67085, France;
| | - Philippe Moreau
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Nathalie Rouas-Freiss
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Danièle Bensoussan
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Céline Huselstein
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| |
Collapse
|
16
|
Nguyen LS, Rouas-Freiss N, Funck-Brentano C, Leban M, Carosella ED, Touraine P, Varnous S, Bachelot A, Salem JE. Influence of hormones on the immunotolerogenic molecule HLA-G: a cross-sectional study in patients with congenital adrenal hyperplasia. Eur J Endocrinol 2019; 181:481-488. [PMID: 31505456 DOI: 10.1530/eje-19-0379] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 09/09/2019] [Indexed: 11/08/2022]
Abstract
BACKGROUND HLA-G is an immune checkpoint molecule, naturally expressed during pregnancy, playing a critical role in the tolerance of the fetal semi-allograft from the maternal immune system. While HLA-G expression levels are associated with progesterone, the influence of other hormones is still unclear. Congenital adrenal hyperplasia (CAH) represents an adequate model to study the hormonal influence on biomarkers as it leads to impaired cortisol biosynthesis and increased progesterone and androgens production due to 21-hydroxylase enzyme deficiency. METHODS In a cross-sectional study of CAH patients matched on sex and age with healthy control, the association between circulating levels of soluble HLA-G and hormones was assessed by use of non-parametric analyses tests. Multivariable linear regressions were performed on normalized data. RESULTS Overall, 83 CAH patients and 69 healthy controls were included. Among CAH patients, all were under glucocorticoid and 52 (62.6%) were under mineralocorticoid supplementation. Compared to controls, CAH patients had increased HLA-G levels (15 vs 8 ng/mL, P = 0.02). In controls, HLA-G level was independently associated with progesterone and estradiol (β = 0.44 (0.35-1.27) and -0.44 (-0.94, -0.26) respectively, both P values = 0.001). In CAH patients, HLA-G level was independently associated with mineralocorticoid supplementation dosage (β = 0.25 (0.04-0.41), P = 0.001) and estradiol (β = -0.22 (-0.57, -0.02), P < 0.001). CONCLUSION CAH patients had higher HLA-G levels than healthy controls. HLA-G level was positively associated with progesterone and corticosteroid supplementation, and negatively with estradiol. The association between mineralocorticoid, renin and HLA-G levels may suggest a role of the renin-angiotensin system in the expression of soluble HLA-G.
Collapse
Affiliation(s)
- Lee S Nguyen
- Department of Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, UNICO AP-HP.6 Cardio-Oncology Program, Pitié-Salpêtrière Hospital, Paris, France
- Department of Cardiothoracic Surgery, Sorbonne Université, Institute of Cardiology, Pitie-Salpetriere University Hospital, ICAN, Paris, France
| | - Nathalie Rouas-Freiss
- Department of Research in Hemato-Immunology (SRHI), CEA, Saint-Louis Institute, UMR U976, Paris, France
| | - Christian Funck-Brentano
- Department of Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, UNICO AP-HP.6 Cardio-Oncology Program, Pitié-Salpêtrière Hospital, Paris, France
| | - Monique Leban
- Department of Endocrinology, Pitie-Salpetriere University Hospital, Sorbonne Universite, ICAN, Paris, France
| | - Edgardo D Carosella
- Department of Research in Hemato-Immunology (SRHI), CEA, Saint-Louis Institute, UMR U976, Paris, France
| | - Philippe Touraine
- Department of Endocrinology, Pitie-Salpetriere University Hospital, Sorbonne Universite, ICAN, Paris, France
- Center for Rare Endocrine Disorders and center for Rare Gynecological Disorders, Paris, France
| | - Shaida Varnous
- Department of Cardiothoracic Surgery, Sorbonne Université, Institute of Cardiology, Pitie-Salpetriere University Hospital, ICAN, Paris, France
| | - Anne Bachelot
- Department of Endocrinology, Pitie-Salpetriere University Hospital, Sorbonne Universite, ICAN, Paris, France
| | - Joe-Elie Salem
- Department of Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, UNICO AP-HP.6 Cardio-Oncology Program, Pitié-Salpêtrière Hospital, Paris, France
- Department of Pharmacology and Medicine, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
17
|
Melo‐Lima BL, Poras I, Passos GA, Carosella ED, Donadi EA, Moreau P. The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells. Immunology 2019; 158:121-135. [PMID: 31322727 PMCID: PMC6742766 DOI: 10.1111/imm.13099] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 07/11/2019] [Indexed: 12/12/2022] Open
Abstract
The Autoimmune Regulator (Aire) protein coordinates the negative selection of developing thymocytes by inducing the expression of hundreds of tissue-specific antigens within the thymic medulla, which is also a primary site of the expression of the immune checkpoint HLA-G molecule. Considering the immunomodulatory properties of Aire and HLA-G, and considering that the role of the constitutive thymus expression of HLA-G has not been elucidated, we studied the effect of AIRE cDNA transfection on HLA-G expression in 4D6 thymic cells and in the HLA-G-positive JEG-3 choriocarcinoma cells. Aire promoted the transactivation of HLA-G gene by increasing the overall transcription, inducing the transcription of at least G1 and G2/G4 isoforms, and incrementing the occurrence and distribution of intracellular HLA-G protein solely in 4D6 thymic cells. Luciferase-based assays and chromatin immunoprecipitation experiments performed in 4D6 cells revealed that Aire targeted at least two regions within the 5'-untranslated regulatory region (5'-URR) extending 1·4 kb from the first ATG initiation codon. The interaction occurs independently of three putative Aire-binding sites. These results indicate that the Aire-induced upregulation of HLA-G in thymic cells is likely to act through the interaction of Aire with specific HLA-G 5'-URR DNA-binding factors. Such a multimeric transcriptional complex might operate in the thymus during the process of promiscuous gene expression.
Collapse
Affiliation(s)
- Breno Luiz Melo‐Lima
- Direction de la Recherche FondamentaleInstitut de Biologie François JacobService de Recherches en Hémato‐ImmunologieHôpital Saint‐LouisCommissariat à l'Energie Atomique et aux Energies AlternativesParisFrance
- Institut de Recherche Saint‐LouisUniversité de ParisUMR976 HIPIHôpital Saint‐LouisUniversité Paris‐DiderotParisFrance
- Division of Clinical ImmunologyDepartment of MedicineRibeirao Preto Medical SchoolUniversity of São PauloRibeirão PretoSão PauloBrazil
| | - Isabelle Poras
- Direction de la Recherche FondamentaleInstitut de Biologie François JacobService de Recherches en Hémato‐ImmunologieHôpital Saint‐LouisCommissariat à l'Energie Atomique et aux Energies AlternativesParisFrance
- Institut de Recherche Saint‐LouisUniversité de ParisUMR976 HIPIHôpital Saint‐LouisUniversité Paris‐DiderotParisFrance
| | - Geraldo Aleixo Passos
- Molecular Immunogenetics GroupDepartment of GeneticsRibeirão Preto Medical SchoolUniversity of São PauloRibeirão PretoSão PauloBrazil
| | - Edgardo D. Carosella
- Direction de la Recherche FondamentaleInstitut de Biologie François JacobService de Recherches en Hémato‐ImmunologieHôpital Saint‐LouisCommissariat à l'Energie Atomique et aux Energies AlternativesParisFrance
- Institut de Recherche Saint‐LouisUniversité de ParisUMR976 HIPIHôpital Saint‐LouisUniversité Paris‐DiderotParisFrance
| | - Eduardo Antonio Donadi
- Division of Clinical ImmunologyDepartment of MedicineRibeirao Preto Medical SchoolUniversity of São PauloRibeirão PretoSão PauloBrazil
| | - Philippe Moreau
- Direction de la Recherche FondamentaleInstitut de Biologie François JacobService de Recherches en Hémato‐ImmunologieHôpital Saint‐LouisCommissariat à l'Energie Atomique et aux Energies AlternativesParisFrance
- Institut de Recherche Saint‐LouisUniversité de ParisUMR976 HIPIHôpital Saint‐LouisUniversité Paris‐DiderotParisFrance
| |
Collapse
|
18
|
Dumont C, Jacquier A, Verine J, Noel F, Goujon A, Wu CL, Hung TM, Desgrandchamps F, Culine S, Carosella ED, Rouas-Freiss N, LeMaoult J. CD8 +PD-1 -ILT2 + T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G. Cancer Immunol Res 2019; 7:1619-1632. [PMID: 31451484 DOI: 10.1158/2326-6066.cir-18-0764] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 04/25/2019] [Accepted: 08/20/2019] [Indexed: 11/16/2022]
Abstract
Only some cancer patients respond to the immune-checkpoint inhibitors being used in the clinic, and other therapeutic targets are sought. Here, we investigated the HLA-G/ILT2 checkpoint in clear-cell renal-cell carcinoma (ccRCC) patients and focused on tumor-infiltrating CD8+ T lymphocytes (TIL) expressing the HLA-G receptor ILT2. Using transcriptomics and flow cytometry, we characterized both peripheral blood and tumor-infiltrating CD8+ILT2+ T cells from cancer patients as late-differentiated CD27-CD28-CD57+ cytotoxic effectors. We observed a clear dichotomy between CD8+ILT2+ and CD8+PD-1+ TIL subsets. These subsets, which were sometimes present at comparable frequencies in TIL populations, barely overlapped phenotypically and were distinguished by expression of exclusive sets of surface molecules that included checkpoint molecules and activating and inhibitory receptors. CD8+ILT2+ TILs displayed a more mature phenotype and higher expression of cytotoxic molecules. In ex vivo functional experiments with both peripheral blood T cells and TILs, CD8+ILT2+ T cells displayed significantly higher cytotoxicity and IFNγ production than their ILT2- (peripheral blood mononuclear cells, PBMC) and PD-1+ (TILs) counterparts. HLA-G expression by target cells specifically inhibited CD8+ILT2+ T-cell cytotoxicity, but not that of their CD8+ILT2- (PBMC) or CD8+PD-1+ (TIL) counterparts, an effect counteracted by blocking the HLA-G/ILT2 interaction. CD8+ILT2+ TILs may therefore constitute an untapped reservoir of fully differentiated cytotoxic T cells within the tumor microenvironment, independent of the PD1+ TILs targeted by immune therapies, and specifically inhibited by HLA-G. These results emphasize the potential of therapeutically targeting the HLA-G/ILT2 checkpoint in HLA-G+ tumors, either concomitantly with anti-PD-1/PD-L1 or in cases of nonresponsiveness to anti-PD-1/PD-L1.
Collapse
Affiliation(s)
- Clement Dumont
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France.,Department of Medical Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Alix Jacquier
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France
| | - Jerome Verine
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France.,Department of Pathology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France and Paris-Diderot University, Paris, France
| | - Floriane Noel
- Institut Curie, PSL Research University, France and INSERM, UMR 932, Paris, France and Université Paris Sud, Université Paris-Saclay, Orsay, France
| | - Annabelle Goujon
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France.,Department of Urology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ching-Lien Wu
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France
| | - Tzu-Min Hung
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,National Taiwan University Hospital, Taipei City, Taiwan, Republic of China; University of Taipei and E-Da Hospital/I-Shou University, Yan-Chau Shiang, Kaohsiung County, Taiwan, Republic of China
| | - François Desgrandchamps
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France.,Department of Urology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Stephane Culine
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France.,Department of Medical Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Edgardo D Carosella
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France
| | - Nathalie Rouas-Freiss
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France.,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France
| | - Joel LeMaoult
- Hemato-Immunology Research Department, CEA-DRF, Saint-Louis Hospital, Paris, France. .,Paris-Diderot University, Sorbonne-Paris-Cité, Paris, France
| |
Collapse
|
19
|
Desgrandchamps F, LeMaoult J, Goujon A, Riviere A, Rivero-Juarez A, Djouadou M, de Gouvello A, Dumont C, Wu CL, Culine S, Verine J, Rouas-Freiss N, Hennequin C, Masson-Lecomte A, Carosella ED. Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8 + T cells. Oncotarget 2018; 9:33160-33169. [PMID: 30237859 PMCID: PMC6145700 DOI: 10.18632/oncotarget.26036] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2018] [Accepted: 08/03/2018] [Indexed: 01/01/2023] Open
Abstract
Background and Objective Recurrence of non-muscle invasive bladder cancer (NMIBC) after initial management occurs in 60–70% of patients. Predictive criteria for recurrence remain only clinical and pathological. The aim of this study was to investigate the prognostic significance of the proportion of checkpoint HLA-G’s receptor ILT2-expressing peripheral CD8+ T cells. Results The proportion of CD4+ILT2+and CD8+ILT2+ T cells was not increased in NMIBC compared to controls. However, a strong association was found between recurrence and CD8+ILT2+ T cell population levels (p = 0.0006). Two-year recurrence-free survival was 83% in patients with less than 18% CD8+ILT2+ T cells, 39% in the intermediary group, and 12% in patients with more than 46% CD8+ILT2+ T cells. Multivariate analyses demonstrated that the proportion of CD8+ILT2+ T cells was an independent predictive factor for recurrence. Adding CD8+ILT2+ T cells population level to clinical variables increased the predictive accuracy of the model by 4.5%. Materials and Methods All patients treated for NMIBC between 2012 and 2014 were included prospectively. Blood samples, tumor and clinico-pathological characteristics were collected. HLA-G expression was measured using IHC, and CD8+ILT2+ T cell levels using flow cytometry. Association between HLA-G and CD8+ILT2+ T cell population levels with NMIBC risk of recurrence was investigated using Cox regression analyses. Prediction was measured using the concordance index statistic. Conclusions We demonstrated a strong association between the proportion of circulating CD8+ILT2+ T cells and NMIBC risk of recurrence. Gain in prediction was substantial. If externally validated, such immunological marker could be integrated to predict NMIBC recurrence.
Collapse
Affiliation(s)
- Francois Desgrandchamps
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Joel LeMaoult
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hématologie, Saint-Louis Hospital, Paris, France
| | - Annabelle Goujon
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Adrien Riviere
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Antonio Rivero-Juarez
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
| | - Malika Djouadou
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Amory de Gouvello
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Clement Dumont
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Medical Oncology, Paris, France
| | - Ching-Lien Wu
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hématologie, Saint-Louis Hospital, Paris, France
| | - Stephane Culine
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Medical Oncology, Paris, France
| | - Jerome Verine
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Pathology, Paris, France
| | - Nathalie Rouas-Freiss
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hématologie, Saint-Louis Hospital, Paris, France
| | - Christophe Hennequin
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Radiotherapy, Paris, France
| | - Alexandra Masson-Lecomte
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France
| | - Edgardo D Carosella
- CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hématologie, Saint-Louis Hospital, Paris, France
| |
Collapse
|
20
|
Svendsen SG, Nilsson LL, Djurisic S, Funck T, Wu CL, Faber C, Falk MK, Singh A, Sørensen TL, Carosella ED, LeMaoult J, Hviid TVF, Nissen MH. Extended HLA-G haplotypes in patients with age-related macular degeneration. HLA 2018; 92:83-89. [PMID: 30009537 DOI: 10.1111/tan.13340] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 06/14/2018] [Accepted: 07/12/2018] [Indexed: 11/29/2022]
Abstract
The study aims to determine if genetic polymorphisms in the human leukocyte antigen (HLA)-G gene are associated with age-related macular degeneration (AMD). HLA-G is important for immunological tolerance, and it is also known to have angiogenic effects. Polymorphisms in the 5'-upstream regulatory region (URR) and 3'-untranslated region (UTR) of HLA-G have been associated with a number of diseases, especially with respect to a 14 bp insertion/deletion (ins/del) polymorphism in the 3'UTR. Full gene sequencing was performed on a cohort of 146 AMD patients and 63 healthy controls aged 60 years or older and HLA-G haplotypes were determined. Analyses were performed on a publicly available gene expression dataset from the NCBI GEO database (accession number GSE29801) from which expression data for HLA-G, -C and -A were extracted. Analysis of the GEO dataset showed that both HLA-G and -C was expressed in the back of the eye and that expression was upregulated in the macular area of AMD. No differences were observed between patients and controls when analysing the distribution of haplotypes in the HLA-G promoter, coding region, 3'UTR or the 14 bp ins/del polymorphism of the 3'UTR. The increased expression of HLA-G in the macula of AMD patients indicates a role of HLA-G in the micro environment as part of the AMD pathogenesis. This is supported by the expression of HLA-C, which has previously been shown to play a role in AMD. The HLA-G haplotype distribution did not display any differences between AMD patients and controls. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Signe Goul Svendsen
- Department of Immunology and Microbiology, University of Copenhagen, Denmark
| | - Line Lynge Nilsson
- Centre for Immune Regulation and Reproductive Immunology (CIRRI), Department of Clinical Biochemistry, Zealand University Hospital, Denmark
- Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen
| | - Snezana Djurisic
- Centre for Immune Regulation and Reproductive Immunology (CIRRI), Department of Clinical Biochemistry, Zealand University Hospital, Denmark
- Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen
| | - Tina Funck
- Centre for Immune Regulation and Reproductive Immunology (CIRRI), Department of Clinical Biochemistry, Zealand University Hospital, Denmark
- Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen
| | - Ching-Lien Wu
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, Paris
| | - Carsten Faber
- Department of Immunology and Microbiology, University of Copenhagen, Denmark
- Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark
| | - Mads Krüger Falk
- Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark
- Clinical Eye Research Unit, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark
| | - Amardeep Singh
- Clinical Eye Research Unit, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark
- Dept. of Ophthalmology, Skåne University Hospital & Lund University, Sweden
| | - Torben Lykke Sørensen
- Clinical Eye Research Unit, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark
- Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen
| | | | - Joël LeMaoult
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, Paris
| | - Thomas Vauvert F Hviid
- Centre for Immune Regulation and Reproductive Immunology (CIRRI), Department of Clinical Biochemistry, Zealand University Hospital, Denmark
- Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen
| | - Mogens Holst Nissen
- Department of Immunology and Microbiology, University of Copenhagen, Denmark
| |
Collapse
|
21
|
Yaghi L, Poras I, Simoes RT, Donadi EA, Tost J, Daunay A, de Almeida BS, Carosella ED, Moreau P. Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2. Oncotarget 2018; 7:63690-63707. [PMID: 27577073 PMCID: PMC5325396 DOI: 10.18632/oncotarget.11628] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 08/20/2016] [Indexed: 12/31/2022] Open
Abstract
HLA-G is an immune checkpoint molecule with specific relevance in cancer immunotherapy. It was first identified in cytotrophoblasts, protecting the fetus from maternal rejection. HLA-G tissue expression is very restricted but induced in numerous malignant tumors such as glioblastoma, contributing to their immune escape. Hypoxia occurs during placenta and tumor development and was shown to activate HLA-G. We aimed to elucidate the mechanisms of HLA-G activation under conditions combining hypoxia-mimicking treatment and 5-aza-2′deoxycytidine, a DNA demethylating agent used in anti-cancer therapy which also induces HLA-G. Both treatments enhanced the amount of HLA-G mRNA and protein in HLA-G negative U251MG glioma cells. Electrophoretic Mobility Shift Assays and luciferase reporter gene assays revealed that HLA-G upregulation depends on Hypoxia Inducible Factor-1 (HIF-1) and a hypoxia responsive element (HRE) located in exon 2. A polymorphic HRE at −966 bp in the 5′UT region may modulate the magnitude of the response mediated by the exon 2 HRE. We suggest that therapeutic strategies should take into account that HLA-G expression in response to hypoxic tumor environment is dependent on HLA-G gene polymorphism and DNA methylation state at the HLA-G locus.
Collapse
Affiliation(s)
- Layale Yaghi
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France.,Lebanese University, School of Medicine, Hadath, Lebanon
| | - Isabelle Poras
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
| | - Renata T Simoes
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France.,Instituto de Ensino e Pesquisa da Santa Casa de Belo Horizonte, IEP/SCBH, Belo Horizonte, Minas Gerais, Brasil
| | - Eduardo A Donadi
- Divisão de Imunologia Clínica, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
| | - Jörg Tost
- Centre d'Etude du Polymorphisme Humain, Fondation Jean-Dausset, Laboratory for Functional Genomics, Paris, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives, Centre National de Genotypage, Laboratory for Epigenetics and Environment, Evry, France
| | - Antoine Daunay
- Centre d'Etude du Polymorphisme Humain, Fondation Jean-Dausset, Laboratory for Functional Genomics, Paris, France
| | - Bibiana Sgorla de Almeida
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France.,Divisão de Imunologia Clínica, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
| | - Edgardo D Carosella
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
| | - Philippe Moreau
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
22
|
Dias FC, Bertol BC, Poras I, Souto BM, Mendes-Junior CT, Castelli EC, Gineau L, Sabbagh A, Rouas-Freiss N, Carosella ED, Donadi EA, Moreau P. The genetic diversity within the 1.4 kb HLA-G 5' upstream regulatory region moderately impacts on cellular microenvironment responses. Sci Rep 2018; 8:5652. [PMID: 29618829 PMCID: PMC5884815 DOI: 10.1038/s41598-018-24009-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 03/15/2018] [Indexed: 12/21/2022] Open
Abstract
The HLA-G 5'URR extending 1.4 kb from the ATG presents a unique set of regulatory elements among HLA genes. Several variable sites have been described that coincide with or are close to these elements, thus HLA-G 5'URR polymorphism might influence the HLA-G expression level. We cloned the ten most frequent HLA-G 5'URR haplotypes to evaluate their activity on a luciferase reporter gene in HLA-G+ cell lines (JEG-3/choriocarcinoma and FON+/melanoma). We also investigated associations between the plasma HLA-G (sHLA-G) levels and the HLA-G 5'URR variability in 157 healthy individuals. Cell lines were transfected with pGL3-Basic vector constructions containing HLA-G 5'URR sequences. The G010101a (in JEG-3) and G010101b (in FON+) haplotypes exhibited higher promoter activity, whereas the G010101d (in JEG-3) and G010102a (in FON+) haplotypes exhibited lower promoter activity. In the presence of HLA-G inducers (interferon-β and progesterone) or repressors (cyclopamine) HLA-G promoter activity was modulated, but certain haplotypes exhibited differential responses. No strict association was observed between plasma sHLA-G levels and the 5'URR haplotypes or genotypes; however, the G010101b haplotype was underrepresented among HLA-G-negative plasmas. Therefore, the HLA-G 5'URR polymorphism may have an impact on the modulation of HLA-G gene expression, but alone provides a limited predictive value for sHLA-G levels in vivo.
Collapse
Affiliation(s)
- Fabrício C Dias
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil.,Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Bruna C Bertol
- Department of Biochemistry and Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Isabelle Poras
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Bruno M Souto
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Celso T Mendes-Junior
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Erick C Castelli
- São Paulo State University (UNESP), Department of Pathology, School of Medicine, Botucatu, State of São, Paulo, ZIP Code 18.618-687, Brazil
| | - Laure Gineau
- UMR 216-MERIT, Institut de Recherche pour le Développement, Faculté de Pharmacie de Paris - Université Paris Descartes, COMUE Sorbonne Paris-Cité, Paris, ZIP Code 75006, France
| | - Audrey Sabbagh
- UMR 216-MERIT, Institut de Recherche pour le Développement, Faculté de Pharmacie de Paris - Université Paris Descartes, COMUE Sorbonne Paris-Cité, Paris, ZIP Code 75006, France
| | - Nathalie Rouas-Freiss
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Edgardo D Carosella
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Eduardo A Donadi
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil.,Department of Biochemistry and Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Philippe Moreau
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France. .,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.
| |
Collapse
|
23
|
Tronik-Le Roux D, Renard J, Vérine J, Renault V, Tubacher E, LeMaoult J, Rouas-Freiss N, Deleuze JF, Desgrandschamps F, Carosella ED. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol Oncol 2017; 11:1561-1578. [PMID: 28815885 PMCID: PMC5664004 DOI: 10.1002/1878-0261.12119] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 07/21/2017] [Accepted: 07/29/2017] [Indexed: 12/14/2022] Open
Abstract
Immune checkpoints are powerful inhibitory molecules that promote tumor survival. Their blockade is now recognized as providing effective therapeutic benefit against cancer. Human leukocyte antigen G (HLA‐G), a recently identified immune checkpoint, has been detected in many types of primary tumors and metastases, in malignant effusions as well as on tumor‐infiltrating cells, particularly in patients with clear cell renal cell carcinoma (ccRCC). Here, in order to define a possible anticancer therapy, we used a molecular approach based on an unbiased strategy that combines transcriptome determination and immunohistochemical labeling, to analyze in‐depth the HLA‐G isoforms expressed in these tumors. We found that the expression of HLA‐G is highly variable among tumors and distinct areas of the same tumor, testifying a marked inter‐ and intratumor heterogeneity. Moreover, our results generate an inventory of novel HLA‐G isoforms which includes spliced forms that have an extended 5′‐region and lack the transmembrane and alpha‐1 domains. So far, these isoforms could not be detected by any method available and their assessment may improve the procedure by which tumors are analyzed. Collectively, our approach provides the first extensive portrait of HLA‐G in ccRCC and reveals data that should prove suitable for the tailoring of future clinical applications.
Collapse
Affiliation(s)
- Diana Tronik-Le Roux
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,UMR_E5, IUH, Hôpital Saint-Louis, Universite Paris Diderot, Sorbonne Paris Cite, France
| | - Julie Renard
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,UMR_E5, IUH, Hôpital Saint-Louis, Universite Paris Diderot, Sorbonne Paris Cite, France
| | - Jérôme Vérine
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Service d'Anatomo-Pathologie, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Victor Renault
- Centre d'Etudes du Polymorphisme Humain, Fondation Jean Dausset, Paris, France
| | - Emmanuel Tubacher
- Centre d'Etudes du Polymorphisme Humain, Fondation Jean Dausset, Paris, France
| | - Joel LeMaoult
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,UMR_E5, IUH, Hôpital Saint-Louis, Universite Paris Diderot, Sorbonne Paris Cite, France
| | - Nathalie Rouas-Freiss
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,UMR_E5, IUH, Hôpital Saint-Louis, Universite Paris Diderot, Sorbonne Paris Cite, France
| | - Jean-François Deleuze
- Centre d'Etudes du Polymorphisme Humain, Fondation Jean Dausset, Paris, France.,Centre National de Génotypage, Institut de Génomique, CEA, Evry, France
| | - François Desgrandschamps
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Service d'Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Edgardo D Carosella
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,UMR_E5, IUH, Hôpital Saint-Louis, Universite Paris Diderot, Sorbonne Paris Cite, France
| |
Collapse
|
24
|
Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, Desgrandchamps F, Carosella ED. Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. Oncoimmunology 2017; 6:e1342023. [PMID: 28932645 DOI: 10.1080/2162402x.2017.1342023] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/22/2017] [Accepted: 06/07/2017] [Indexed: 02/08/2023] Open
Abstract
The establishment and maintenance of anti-tumor immune responses are the objectives of cancer immunotherapy. Despite recent promising advances, the effectiveness of these approaches has been limited by the multiple immunosuppressive mechanisms developed by tumors (checkpoint). The aim of the present study was to demonstrate intratumor heterogeneity at the levels of immune escape strategies and tumor-host relationships. We focused on well-known checkpoints such as PD1/PDL1 and on a new checkpoint involving HLA-G and its receptors ILT2/ILT4. A prospective study was performed on 19 renal-cell carcinoma patients that were included during hospitalization for surgical tumor resection. Different areas of the tumor were collected for each patient and subjected to both immunohistochemical and flow cytometry analysis. Immune cells from peripheral blood were concomitantly analyzed for each patient. Our results show the heterogeneous expression of PD1/PDL1 and HLA-G/ILT in the various areas of the same tumor. Intratumor heterogeneity was found both at tumor cell and infiltrating immune cell levels. From a clinical point of view, this work highlights the functional redundancies of checkpoints and the need to adapt personalized poly-immunotherapy.
Collapse
Affiliation(s)
- Nathalie Rouas-Freiss
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France
| | - Joel LeMaoult
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France
| | - Jérôme Verine
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France.,Service d'Anatomo-Pathologie, AP-HP, Hopital Saint-Louis, Paris, France
| | - Diana Tronik-Le Roux
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France
| | - Stéphane Culine
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France.,Service d'Oncologie Médicale, AP-HP, Hopital Saint-Louis, Paris, France
| | - Christophe Hennequin
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France.,Service de Radiothérapie, AP-HP, Hopital Saint-Louis, Paris, France
| | - François Desgrandchamps
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France.,Service d'Urologie, AP-HP, Hopital Saint-Louis, Paris, France
| | - Edgardo D Carosella
- CEA, Direction de la Recherche Fondamentale (DRF), Service de Recherche en Hemato-Immunologie (SRHI), Paris, France.,Universite Paris Diderot, Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Paris, France
| |
Collapse
|
25
|
Poras I, Yaghi L, Martelli-Palomino G, Mendes-Junior CT, Muniz YCN, Cagnin NF, Sgorla de Almeida B, Castelli EC, Carosella ED, Donadi EA, Moreau P. Haplotypes of the HLA-G 3' Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially. PLoS One 2017; 12:e0169032. [PMID: 28045999 PMCID: PMC5207740 DOI: 10.1371/journal.pone.0169032] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 12/09/2016] [Indexed: 12/11/2022] Open
Abstract
The immune checkpoint HLA-G prevents maternal rejection of the fetus and contributes in cancer invasion and acceptance of allografts. The 5’ and 3’ regulatory regions of the HLA-G gene are polymorphic and balancing selection probably maintains this variability. It is proposed that nucleotide variations may affect the level of HLA-G expression. To investigate this issue we aimed to analyze how haplotypes of the 3’ untranslated region (3’UTR) with highest worldwide frequencies, namely UTR-1, UTR-2, UTR-3, UTR-4, UTR-5, UTR-18 and UTR-7, impact the expression of a luciferase reporter gene in vitro. Experiments performed with the HLA-G positive cell lines JEG-3 (choricarcinoma) and FON (melanoma), and with the HLA-G negative cell lines M8 (melanoma) and U251MG (glioblastoma) showed that the HLA-G 3’UTR polymorphism influences the response to endogenous cellular factors and may vary according to the cell type. UTR-5 and UTR-7 impact the activity of luciferase the most whereas UTR-2, UTR-3, UTR-4, and UTR-18 have intermediate impact, and UTR-1 has the lowest impact. These results corroborate the previous associations between amounts of plasma sHLA-G levels and 3’UTR haplotypes in healthy individuals and reinforce that 3’UTR typing may be a predictor of the genetic predisposition of an individual to express different levels of HLA-G.
Collapse
Affiliation(s)
- Isabelle Poras
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
| | - Layale Yaghi
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- Lebanese University, School of Medicine, Hadath, Lebanon
| | - Gustavo Martelli-Palomino
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- Programa de Pós-graduação em Ciências da Saúde, Centro de Ciências da Saúde. Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brasil
| | - Celso T. Mendes-Junior
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Yara Costa Netto Muniz
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- Departamento de Biologia Celular, Embriologia e Genética, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, Brasil
| | - Natalia F. Cagnin
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Bibiana Sgorla de Almeida
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- Departamento de Biologia Celular, Embriologia e Genética, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, Brasil
- Divisão de Imunologia Clínica, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
| | - Erick C. Castelli
- Department of Pathology, School of Medicine, Universidade Estadual Paulista, Unesp, Botucatu, São Paulo, Brazil
| | - Edgardo D. Carosella
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
| | - Eduardo A. Donadi
- Divisão de Imunologia Clínica, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
| | - Philippe Moreau
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
- Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France
- * E-mail:
| |
Collapse
|
26
|
Du WJ, Reppel L, Leger L, Schenowitz C, Huselstein C, Bensoussan D, Carosella ED, Han ZC, Rouas-Freiss N. Mesenchymal Stem Cells Derived from Human Bone Marrow and Adipose Tissue Maintain Their Immunosuppressive Properties After Chondrogenic Differentiation: Role of HLA-G. Stem Cells Dev 2016; 25:1454-69. [PMID: 27465875 DOI: 10.1089/scd.2016.0022] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Mesenchymal stem cells (MSC) have emerged as alternative sources of stem cells for regenerative medicine because of their multipotency and strong immune-regulatory properties. Also, human leukocyte antigen G (HLA-G) is an important mediator of MSC-mediated immunomodulation. However, it is unclear whether MSC retain their immune-privileged potential after differentiation. As promising candidates for cartilage tissue engineering, the immunogenic and immunomodulatory properties of chondro-differentiated MSC (chondro-MSC) require in-depth exploration. In the present study, we used the alginate/hyaluronic acid (Alg/HA) hydrogel scaffold and induced both bone marrow- and adipose tissue-derived MSC into chondrocytes in three-dimensional condition. Then, MSC before and after chondrocyte differentiation were treated or not with interferon γ and tumor necrosis factor α mimicking inflammatory conditions and were compared side by side using flow cytometry, mixed lymphocyte reaction, and immunostaining assays. Results showed that chondro-MSC were hypoimmunogenic and could exert immunosuppression on HLA-mismatched peripheral blood mononuclear cells as well as undifferentiated MSC did. This alloproliferation inhibition mediated by MSC or chondro-MSC was dose dependent. Meanwhile, chondro-MSC exerted inhibition on natural killer cell-mediated cytolysis. Also, we showed that HLA-G expression was upregulated in chondro-MSC under hypoxia context and could be boosted in allogenic settings. Besides, the Alg/HA hydrogel scaffold was hypoimmunogenic and its addition for supporting MSC chondrocyte differentiation did not modify the immune properties of MSC. Finally, considering their chondro-regenerative potential and their retained immunosuppressive capacity, MSC constitute promising allogenic sources of stem cells for cartilage repair.
Collapse
Affiliation(s)
- Wen-Jing Du
- 1 CEA, Direction de la Recherche Fondamentale (DRF), Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis , IUH, Paris, France .,2 The State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Disease , Chinese Academy of Medical Science, Peking Union Medical College, Tianjin, China
| | - Loic Reppel
- 3 Cell and Tissue Banking Unit and Research Federation FR 3209, Nancy University Hospital , Nancy, France .,4 UMR CNRS 7365 and FR 3209 CNRS-INSERM-UL-CHU, Lorraine University , Vandoeuvre-Les-Nancy, France .,5 Microbiology-Immunology Department, Faculty of Pharmacy, Lorraine University , Nancy, France
| | - Léonore Leger
- 3 Cell and Tissue Banking Unit and Research Federation FR 3209, Nancy University Hospital , Nancy, France .,4 UMR CNRS 7365 and FR 3209 CNRS-INSERM-UL-CHU, Lorraine University , Vandoeuvre-Les-Nancy, France .,5 Microbiology-Immunology Department, Faculty of Pharmacy, Lorraine University , Nancy, France
| | - Chantal Schenowitz
- 1 CEA, Direction de la Recherche Fondamentale (DRF), Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis , IUH, Paris, France .,6 Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Universite Paris Diderot , Paris, France
| | - Celine Huselstein
- 4 UMR CNRS 7365 and FR 3209 CNRS-INSERM-UL-CHU, Lorraine University , Vandoeuvre-Les-Nancy, France
| | - Danièle Bensoussan
- 3 Cell and Tissue Banking Unit and Research Federation FR 3209, Nancy University Hospital , Nancy, France .,4 UMR CNRS 7365 and FR 3209 CNRS-INSERM-UL-CHU, Lorraine University , Vandoeuvre-Les-Nancy, France .,5 Microbiology-Immunology Department, Faculty of Pharmacy, Lorraine University , Nancy, France
| | - Edgardo D Carosella
- 1 CEA, Direction de la Recherche Fondamentale (DRF), Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis , IUH, Paris, France .,6 Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Universite Paris Diderot , Paris, France
| | - Zhong-Chao Han
- 2 The State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Disease , Chinese Academy of Medical Science, Peking Union Medical College, Tianjin, China
| | - Nathalie Rouas-Freiss
- 1 CEA, Direction de la Recherche Fondamentale (DRF), Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis , IUH, Paris, France .,6 Sorbonne Paris Cite, IUH, Hopital Saint-Louis, UMR_E5, Universite Paris Diderot , Paris, France
| |
Collapse
|
27
|
von Websky MW, Kitamura K, Ludwig-Portugall I, Kurts C, von Laffert M, LeMaoult J, Carosella ED, Abu-Elmagd K, Kalff JC, Schäfer N. Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation. PLoS One 2016; 11:e0158907. [PMID: 27404095 PMCID: PMC4942037 DOI: 10.1371/journal.pone.0158907] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 06/23/2016] [Indexed: 11/18/2022] Open
Abstract
The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8+ T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4+ populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4+/CD25+/FoxP3+Treg-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8+ T-cell populations either directly or by induction of non-classical Treg populations.
Collapse
Affiliation(s)
| | - Koji Kitamura
- Department of Surgery, University Hospital of Bonn, Bonn, Germany
- Department of Hepatobiliary Pancreatic Surgery and Transplantation, Kyoto University Hospital, Kyoto, Japan
| | | | - Christian Kurts
- Institute for Experimental Immunology, University of Bonn, Germany
| | | | - Joel LeMaoult
- CEA, iMETI, Research Division in Hematology and Immunology, Saint-Louis Hospital, Paris, France
| | - Edgardo D. Carosella
- CEA, iMETI, Research Division in Hematology and Immunology, Saint-Louis Hospital, Paris, France
| | - Kareem Abu-Elmagd
- Transplant Center, Cleveland Clinic, Cleveland, Ohio, United States of America
| | - Joerg C. Kalff
- Department of Surgery, University Hospital of Bonn, Bonn, Germany
| | - Nico Schäfer
- Department of Surgery, University Hospital of Bonn, Bonn, Germany
- * E-mail:
| |
Collapse
|
28
|
Gallegos CE, Michelin S, Dubner D, Carosella ED. Immunomodulation of classical and non-classical HLA molecules by ionizing radiation. Cell Immunol 2016; 303:16-23. [PMID: 27113815 DOI: 10.1016/j.cellimm.2016.04.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 04/13/2016] [Accepted: 04/16/2016] [Indexed: 01/06/2023]
Abstract
Radiotherapy has been employed for the treatment of oncological patients for nearly a century, and together with surgery and chemotherapy, radiation oncology constitutes one of the three pillars of cancer therapy. Ionizing radiation has complex effects on neoplastic cells and on tumor microenvironment: beyond its action as a direct cytotoxic agent, tumor irradiation triggers a series of alterations in tumoral cells, which includes the de novo synthesis of particular proteins and the up/down-regulation of cell surface molecules. Additionally, ionizing radiation may induce the release of "danger signals" which may, in turn lead to cellular and molecular responses by the immune system. This immunomodulatory action of ionizing radiation highlights the importance of the combined use (radiotherapy plus immunotherapy) for cancer healing. Major histocompatibility complex antigens (also called Human Leukocyte Antigens, HLA in humans) are one of those molecules whose expression is modulated after irradiation. This review summarizes the modulatory properties of ionizing radiation on the expression of HLA class I (classical and non-classical) and class II molecules, with special emphasis in non-classical HLA-I molecules.
Collapse
Affiliation(s)
- Cristina E Gallegos
- Radiopathology Laboratory, Nuclear Regulatory Authority (ARN), Buenos Aires, Argentina; Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Universidad Nacional del Sur (UNS), CONICET, Toxicology laboratory, Bahía Blanca, Argentina(2).
| | - Severino Michelin
- Radiopathology Laboratory, Nuclear Regulatory Authority (ARN), Buenos Aires, Argentina
| | - Diana Dubner
- Radiopathology Laboratory, Nuclear Regulatory Authority (ARN), Buenos Aires, Argentina
| | - Edgardo D Carosella
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Paris, France; University Paris Diderot, Sorbonne Paris Cité, UMR E-5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France
| |
Collapse
|
29
|
Wu CL, Svendsen SG, Riviere A, Desgrandchamps F, Carosella ED, LeMaoult J. Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4. Hum Immunol 2016; 77:720-6. [PMID: 26874236 DOI: 10.1016/j.humimm.2016.01.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 01/20/2016] [Accepted: 01/21/2016] [Indexed: 10/22/2022]
Abstract
Human leukocyte antigen (HLA)-G is an immune-inhibitory molecule that exerts its function via interaction with two main inhibitory receptors: ILT2 and ILT4. This interaction is considered to be an immune checkpoint. HLA-G can be found as a soluble molecule, but it is not known if its receptors can also be found as soluble molecules. In this work, we present a multiplex luminex-based assay to measure soluble ILT2 (sILT2) and soluble ILT4 (sILT4) molecules together. It is based on two antibody pairs, GHI/75 and HP-F1-PE for ILT2 and 27D6 and 42D1-PE for ILT4. The characterization of our method reveals that it specifically detects the free soluble forms of sILT2 and sILT4, and not those complexed to HLA Class I molecules such as their ligand of highest affinity HLA-G. A study on two small cohorts of cancer patients demonstrated that soluble ILT2 and ILT4 molecules were of low abundance in the plasma of healthy controls, but that elevated levels of plasmatic sILT2 were present in non-muscle-infiltrating bladder cancer patients. This demonstrated that the titration test is indeed working, and that soluble ILT2 molecules do exist in pathological contexts, which relevance may now be sought on larger cohorts and other pathologies.
Collapse
Affiliation(s)
- Ching-Lien Wu
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, 1 Avenue Claude Vellefaux, Bat Lailler, 75475 Paris Cedex 10, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - Signe Goul Svendsen
- Department of Immunology and Microbiology, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark
| | - Adrien Riviere
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, 1 Avenue Claude Vellefaux, Bat Lailler, 75475 Paris Cedex 10, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France; AP-HP, Saint-Louis Hospital, Department of Urology, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - François Desgrandchamps
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, 1 Avenue Claude Vellefaux, Bat Lailler, 75475 Paris Cedex 10, France; AP-HP, Saint-Louis Hospital, Department of Urology, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - Edgardo D Carosella
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, 1 Avenue Claude Vellefaux, Bat Lailler, 75475 Paris Cedex 10, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - Joël LeMaoult
- Hemato-Immunology Research Department, CEA, Hospital Saint Louis, 1 Avenue Claude Vellefaux, Bat Lailler, 75475 Paris Cedex 10, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France.
| |
Collapse
|
30
|
Dupin C, Lhuillier E, Létuvé S, Carosella ED, Pretolani M, Rouas-Freiss N, Brugière O. Altération des propriétés immunosuppressives de l’épithélium bronchique chez les greffés pulmonaires : modèle ex vivo de réponse T-allogénique. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015; 68:267-79. [PMID: 25824720 DOI: 10.1016/j.eururo.2015.02.032] [Citation(s) in RCA: 166] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 02/25/2015] [Indexed: 02/06/2023]
Abstract
CONTEXT Overexpression of immune checkpoint molecules affects tumor-specific T-cell immunity in the cancer microenvironment, and can reshape tumor progression and metastasis. Antibodies targeting checkpoints could restore antitumor immunity by blocking the inhibitory receptor-ligand interaction. OBJECTIVE To analyze data and current trends in immune checkpoint targeting therapy for urologic cancers. EVIDENCE ACQUISITION Systematic literature search for clinical trials in the PubMed and Cochrane databases up to August 2014 according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Endpoints included oncologic results, tumor response rates, safety, and tolerability. EVIDENCE SYNTHESIS Anti-CTLA-4 monotherapy has demonstrated biochemical responses in prostate cancer. One phase 3 trial assessing ipilimumab efficacy in castration-resistant disease was negative overall. Nevertheless, ipilimumab may significantly improve overall survival compared with placebo in subgroups of patients with favorable prognostic features. In renal cancer, phase 1 trials showed interesting stabilization or long-lasting objective response rates approaching 50% using anti-PD-1/PD-L1 drugs in heavily pretreated metastatic patients. In bladder cancer, one phase 2 trial indicated a good safety profile for ipilimumab as a neoadjuvant drug before radical cystectomy. Overall, immune-related effects such as colitis and dermatitis were common and well tolerated. CONCLUSIONS Our systematic review shows that antibodies blocking immune checkpoints offer interesting and long-lasting response rates in heavily pretreated patients with advanced urologic cancers. More promising results are currently provided by anti-CTLA-4 antibodies in prostate cancer and by PD-1/PD-L1 inhibitors in renal cancer. These should encourage new clinical trials of immune therapy combinations and immunotherapy monotherapy combined with conventional anticancer drugs. In bladder cancer, the use of targeted immunotherapy still remains underevaluated; however, preliminary results reported at recent conferences seem encouraging. PATIENT SUMMARY Data from studies support the activity and safety of immune checkpoint inhibitors in urologic cancers, alone or in combination with conventional cancer therapies. Encouraging data in other oncologic fields could translate into interesting responses in urological cancers.
Collapse
Affiliation(s)
- Edgardo D Carosella
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France.
| | | | - Joel LeMaoult
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France
| | - Francois Desgrandchamps
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France; University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France; Urology Department, Saint-Louis Hospital, Paris, France
| |
Collapse
|
32
|
LeMaoult J, Caumartin J, Daouya M, Switala M, Rebmann V, Arnulf B, Carosella ED. Trogocytic intercellular membrane exchanges among hematological tumors. J Hematol Oncol 2015; 8:24. [PMID: 25887663 PMCID: PMC4371622 DOI: 10.1186/s13045-015-0114-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 01/17/2015] [Indexed: 01/01/2023] Open
Abstract
Trogocytosis is the transfer of plasma membrane fragments and the molecules they contain between one donor and one acceptor/acquirer cell. Through trogocytosis, acceptor cells temporarily display and use cell-surface molecules they do not express themselves, but borrow from other cells. Here, we investigated whether liquid tumors possessed a trogocytic capability, if immune escape molecules could be acquired by tumor cells, transferred between cells of the same tumor, and if this could benefit the tumor as a whole.For this, we investigated trogocytosis in hematological cell lines and freshly isolated hematological tumor cells. We demonstrate that hematological tumor lines possess a trogocytic capability that allows them to capture membranes that contain the immune-inhibitory molecule HLA-G from allogeneic as well as from autologous sources. We further show that freshly isolated hematological tumor cells also possess these capabilities. This work reports for the first time the trogocytic capabilities of liquid tumor cells and introduces the notion of immune escape strategy sharing among tumor cells through trogocytosis of membrane-bound immune-inhibitory molecules.
Collapse
Affiliation(s)
- Joel LeMaoult
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. .,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France.
| | - Julien Caumartin
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. .,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France. .,Biology and Biotechnology Ph.D. Program, Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
| | - Marina Daouya
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. .,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France.
| | - Magdalena Switala
- Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
| | - Vera Rebmann
- Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
| | - Bertrand Arnulf
- Département d'Immuno-Hématologie, Hôpital Saint-Louis, Paris, France.
| | - Edgardo D Carosella
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. .,University Paris Diderot, Sorbonne Paris Cité, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France.
| |
Collapse
|
33
|
Dupin C, Lhuillier E, Létuvé S, Carosella ED, Pretolani M, Rouas-Freiss N, Brugière O. Altération des propriétés immunosuppressives de l’épithélium bronchique chez les greffés pulmonaires : modèle ex vivo de réponse T-allogénique. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Brugière O, Thabut G, Krawice-Radanne I, Rizzo R, Dauriat G, Danel C, Suberbielle C, Mal H, Stern M, Schilte C, Pretolani M, Carosella ED, Rouas-Freiss N. Role of HLA-G as a predictive marker of low risk of chronic rejection in lung transplant recipients: a clinical prospective study. Am J Transplant 2015; 15:461-71. [PMID: 25488753 DOI: 10.1111/ajt.12977] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Revised: 08/04/2014] [Accepted: 08/07/2014] [Indexed: 01/25/2023]
Abstract
Human leukocyte antigen G (HLA-G) expression is thought to be associated with a tolerance state following solid organ transplantation. In a lung transplant (LTx) recipient cohort, we assessed (1) the role of HLA-G expression as a predictor of graft acceptance, and (2) the relationship between (i) graft and peripheral HLA-G expression, (ii) HLA-G expression and humoral immunity and (iii) HLA-G expression and lung microenvironment. We prospectively enrolled 63 LTx recipients (median follow-up 3.26 years [min: 0.44-max: 5.03]). At 3 and 12 months post-LTx, we analyzed graft HLA-G expression by immunohistochemistry, plasma soluble HLA-G (sHLA-G) level by enzyme-linked immunosorbent assay, bronchoalveolar lavage fluid (BALF) levels of cytokines involved in chronic lung allograft dysfunction (CLAD) and anti-HLA antibodies (Abs) in serum. In a time-dependent Cox model, lung HLA-G expression had a protective effect on CLAD occurrence (hazard ratio: 0.13 [0.03-0.58]; p = 0.008). The same results were found when computing 3-month and 1-year conditional freedom from CLAD (p = 0.03 and 0.04, respectively [log-rank test]). Presence of anti-HLA Abs was inversely associated with graft HLA-G expression (p = 0.02). Increased BALF level of transforming growth factor-β was associated with high plasma sHLA-G level (p = 0.02). In conclusion, early graft HLA-G expression in LTx recipients with a stable condition was associated with graft acceptance in the long term.
Collapse
Affiliation(s)
- O Brugière
- Service de Pneumologie B et de Transplantation Pulmonaire, Centre Hospitalier Universitaire (CHU) Bichat-Claude Bernard, Paris, France; Faculté de Médecine Denis Diderot, Université Paris 7, Paris, France; Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; DHU Fire, Paris, France; CEA, Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France; Sorbonne Paris Cité, University Paris Diderot, IUH, Hopital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Naji A, Rouas-Freiss N, Durrbach A, Carosella ED, Sensébé L, Deschaseaux F. Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 2014; 31:2296-303. [PMID: 23922260 DOI: 10.1002/stem.1494] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2012] [Revised: 07/08/2013] [Accepted: 07/10/2013] [Indexed: 12/13/2022]
Abstract
Both human leukocyte antigen G (HLA-G) and multipotential mesenchymal stem/stromal cells (MSCs) exhibit immunomodulatory functions. In allogeneic tranplantation, the risks of acute and chronic rejection are still high despite improvement in immunosuppressive treatments, and the induction of a state of tolerance to alloantigens is not achieved. Immunomodulatory properties of MSCs and HLA-G in human allogeneic tranplantation to induce tolerance appears attractive and promising. Interestingly, we and others have demonstrated that MSCs can express HLA-G. In this review, we focus on the expression of HLA-G by MSCs and discuss how to ensure and improve the immunomodulatory properties of MSCs by selectively targeting MSCs expressing HLA-G (MSCs(HLA-G+)). We also discuss the possible uses of MSCs(HLA-G+) for therapeutic purposes, notably, to overcome acute and chronic immune rejection in solid-organ allogeneic transplantation in humans. Since MSCs are phenotypically and functionally heterogeneous, it is of primary interest to have specific markers ensuring that they have strong immunosuppressive potential and HLA-G may be a valuable candidate.
Collapse
Affiliation(s)
- Abderrahim Naji
- CEA, Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France
| | | | | | | | | | | |
Collapse
|
36
|
Leibler C, Matignon M, Pilon C, Montespan F, Bigot J, Lang P, Carosella ED, Cohen J, Rouas-Freiss N, Grimbert P, Menier C. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells. Am J Transplant 2014; 14:1173-82. [PMID: 24730563 DOI: 10.1111/ajt.12721] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 02/05/2014] [Accepted: 02/24/2014] [Indexed: 01/25/2023]
Abstract
Phase III clinical studies have shown that kidney transplant (KT) recipients treated with the costimulation blocker belatacept exhibited a better renal allograft function and lower donor-specific anti-HLA immunization when compared to recipients treated with calcineurin inhibitors (CNI). We analyzed B cell phenotype in KT recipients treated with belatacept and stable renal function (N = 13). Results were compared to those observed in stable patients treated with CNI (N = 12), or with chronic antibody-mediated rejection (N = 5). Both transcriptional profile and phenotypic characterization of peripheral B cells were performed by real-time polymerase chain reaction and flow cytometry, respectively. In belatacept group, the frequency and absolute number of transitional B cells as defined by both phenotypes: CD19(+) CD24(hi) CD38(hi) and CD19(+) IgD(hi) CD38(hi) CD27(-) , as well as naïve B cells were significantly higher compared with CNI group. B cell activating factor (BAFF) and BAFF receptor mRNA levels were significantly lower in belatacept group than in CNI group. These results show for the first time that belatacept influences B cell compartment by favoring the occurrence of transitional B cells with potential regulatory properties, as described in operational tolerant patients. This role may explain the lower alloimmunization rate observed in belatacept-treated patients.
Collapse
Affiliation(s)
- C Leibler
- Nephrology and Transplantation Department, CHU Henri Mondor, APHP, Créteil, France; Unité Inserm U955, équipe 21 and CIC Biothérapies 504, CHU Henri Mondor, APHP, Paris XII University, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, Rouas-Freiss N. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer 2014; 135:2107-17. [PMID: 24623585 DOI: 10.1002/ijc.28845] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Accepted: 02/19/2014] [Indexed: 01/01/2023]
Abstract
Human leukocyte antigen-G (HLA-G) expression by tumors has been evidenced in numerous malignancies in association with poor prognosis and resistance to immunotherapy in humans. Particularly, soluble form of HLA-G was measured at high concentrations in malignant effusions and plasma from cancer patients, and inhibits antitumor immune cells in vitro through interaction with immunoglobulin-like transcript (ILT) receptors. Nevertheless, in vivo study demonstrating that HLA-G secretion by tumor cells allows their escape from immunosurveillance remained to be established. Despite nondescribed murine homolog, direct functional interaction of HLA-G with murine paired immunoglobulin-like receptor (PIR)-B, ortholog of human ILT receptors, enables to investigate its role in vivo. Immunocompetent mice were injected either with syngeneic tumor cells co-expressing HLA-G5, the main soluble HLA-G isoform, and the conformation stabilizer human β2-microglubulin (hβ2m), or with hβ2m+ HLA-G5- tumor cells. hβ2m expressed at both tumor cell surface acted as a tumor antigen triggering a specific humoral response. Interestingly, although hβ2m+ HLA-G5- tumors were rejected, secreted HLA-G5 provided hβ2m+ HLA-G5+ tumors a protection against hβ2m-elicited immune rejection, enabling such immunogenic tumors to grow similarly to a poorly immunogenic tumor. HLA-G5 tumor expression was associated with local and peripheral immunosuppression, characterized by dampened anti-hβ2m B-cell response, quantitative and functional T-and B-cell defects, accumulation of myeloid-derived suppressor cells able to inhibit T-cell proliferation and reduced T- and B-cell tumor infiltrate. Our study provides the first in vivo proof that soluble HLA-G counteracts tumor rejection and reinforces the importance to consider HLA-G as a promising target to optimize current cancer immunotherapies.
Collapse
Affiliation(s)
- Laure Loumagne
- CEA, IMETI, Service de Recherches en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France; Institut Universitaire d'Hematologie (IUH), Hopital Saint-Louis, UMR_E5, Universite Paris-Diderot-Paris-7, Paris, France
| | | | | | | | | | | |
Collapse
|
38
|
Carosella ED. [HLA-G: from feto-maternal tolerance to organ acceptance]. Bull Acad Natl Med 2014; 198:801-812. [PMID: 26753410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
HLA-G is a nonclassical class I molecule that differs from classical antigens by its restricted expression, very low polymorphism, expression of 7 different protein isoforms, and immune tolerance-inducing activity. HLA-G plays a key role in feto-maternal tolerance. Its interaction with three specific receptors expressed on immune cells (T, B, natural killer and antigen-presenting cells) allows it to act at all levels of the immune response. HLA-G can also be expressed by tumor cells and their microenvironment, endowing them with significant local tolerance. The same is true in some inflammatory and viral diseases.
Collapse
|
39
|
Naji A, Menier C, Morandi F, Agaugué S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N. Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses. J I 2014; 192:1536-46. [DOI: 10.4049/jimmunol.1300438] [Citation(s) in RCA: 113] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
40
|
Gallegos CE, Michelin S, Trasci SB, Lobos EA, Dubner D, Carosella ED. HLA-G1 increases the radiosensitivity of human tumoral cells. Cell Immunol 2014; 287:106-11. [PMID: 24487034 DOI: 10.1016/j.cellimm.2014.01.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 01/05/2014] [Accepted: 01/07/2014] [Indexed: 11/30/2022]
Abstract
Different molecules regulate the response of tumoral tissues to ionizing radiation. The objective of this work was to determine if HLA-G1 expression modulates the radiosensitivity of human tumoral cell lines. To this end, human melanoma M8 and human erythroleukemia K562 cell lines, with their correspondent HLA-G1 negative and positive variants, were gamma irradiated and the survival frequency was determined by clonogenic assay. The survival fraction of HLA-G1 expressing cells was around 60% of HLA-G1 negative cells. The generation of acidic vesicular organelles was higher in HLA-G1 positive cells. Apoptosis levels showed statistically significant differences only in K562 cells, whereas the variation in G2/M cycle progression was only significant in M8 cells. In addition, irradiation diminished cell-surface HLA-G1 and increased soluble HLA-G1 levels. Soluble HLA-G1 has no influence on cell survival in any cell line. In summary, we could demonstrate that HLA-G1 confers higher radiosensitivity to HLA-G1 expressing cells.
Collapse
Affiliation(s)
- Cristina E Gallegos
- Radiopathology Laboratory, Autoridad Regulatoria Nuclear (ARN), Buenos Aires, Argentina; Toxicology Laboratory, Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina
| | - Severino Michelin
- Radiopathology Laboratory, Autoridad Regulatoria Nuclear (ARN), Buenos Aires, Argentina.
| | - Sofía Baffa Trasci
- Radiopathology Laboratory, Autoridad Regulatoria Nuclear (ARN), Buenos Aires, Argentina
| | | | - Diana Dubner
- Radiopathology Laboratory, Autoridad Regulatoria Nuclear (ARN), Buenos Aires, Argentina
| | - Edgardo D Carosella
- Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Paris, France; University Paris Diderot, Sorbonne Paris Cité, UMR E-5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France
| |
Collapse
|
41
|
Abstract
The human leukocyte antigen (HLA)-G is a tolerogenic molecule, whose expression by allografts is associated with better acceptance. An increasing interest in producing HLA-G as a clinical-grade molecule for therapy use is impaired by its complexity and limited stability. Our purpose was to engineer simpler and more stable HLA-G-derived molecules than the full-length HLA-G trimolecular complex that are also tolerogenic, functional as soluble molecules, and compatible with good manufacturing practice (GMP) production conditions. We present two synthetic molecules: (α3-L)x2 and (α1-α3)x2 polypeptides. We show their capability to bind the HLA-G receptor LILRB2 and their functions in vitro and in vivo. The (α1-α3)x2 polypeptide proved to be a potent tolerogenic molecule in vivo: One treatment of skin allograft recipient mice with (α1-α3)x2 was sufficient to significantly prolong graft survival, and four weekly treatments induced complete tolerance. Furthermore, (α1-α3)x2 was active as a soluble molecule and capable of inhibiting the proliferation of tumor cell lines, as does the full length HLA-G trimolecular complex. Thus, the synthetic (α1-α3)x2 polypeptide is a stable and simpler alternative to the full-length HLA-G molecule. It can be produced under GMP conditions, it functions as a soluble molecule, and it is at least as tolerogenic as HLA-G in vivo.
Collapse
Affiliation(s)
- Joel LeMaoult
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Paris, France.
| | | | | | | | | | | |
Collapse
|
42
|
Carosella ED. Opening address to the 6th international conference on HLA-G. Hum Immunol 2013; 74:404. [DOI: 10.1016/j.humimm.2012.11.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 11/09/2012] [Accepted: 11/28/2012] [Indexed: 10/27/2022]
|
43
|
Abstract
The non-classical human leukocyte antigen (HLA) Class I molecule HLA-G is best known for its tolerogenic function at the maternal-fetal interface, where it protects the fetus from destruction by the immune system of its mother. Yet, HLA-G has been the topic of intense investigations and its functions reach much further than originally believed. International conferences on HLA-G have taken place every 3 years since 1998, and the Sixth International Conference on HLA-G, that took place in Paris in July 2012. It counted 180 attendees from 28 countries, 35 speakers in plenary sessions, and 63 presentations of research in symposia and poster sessions, bringing new insight in HLA-G research. Here we summarize the major advances on the function and nature of HLA-G molecule that were reported, with particular interest on the findings in new mechanisms of action through regulatory cells, its relevance in cancer as well as in the molecular structure and functions of HLA-G, which are key for its clinical application.
Collapse
Affiliation(s)
- M Loustau
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France
| | | | | | | |
Collapse
|
44
|
Wastowski IJ, Simões RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Flajollet S, Jensen SS, Ferrone S, Carosella ED, Kristensen BW, Moreau P. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. Am J Pathol 2012; 182:540-52. [PMID: 23219427 DOI: 10.1016/j.ajpath.2012.10.021] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2011] [Revised: 10/22/2012] [Accepted: 10/25/2012] [Indexed: 12/31/2022]
Abstract
Human leukocyte antigen-G (HLA-G) is a nonclassical major histocompatibility complex (MHC) class I molecule involved in immune tolerance processes, playing an important role in the maintenance of the semi-allogeneic fetus. Although HLA-G expression is restricted in normal tissues, it is broadly expressed in malignant tumors and may favor tumor immune escape. We analyzed HLA-G protein and mRNA expression in tumor samples from patients with glioblastoma collected in France, Denmark, and Brazil. We found HLA-G protein expression in 65 of 108 samples and mRNA in 20 of 21 samples. The absence of HLA-G protein expression was associated with a better long-term survival rate. The mechanisms underlying HLA-G gene expression were investigated in glioma cell lines U251MG, D247MG, and U138MG. Induction of HLA-G transcriptional activity was dependent of 5-aza-2'-deoxycytidine treatment and enhanced by interferon-γ. HLA-G protein expression was observed in U251MG cells only. These cells exhibited a permissive chromatin state at the HLA-G gene promoter and the highest levels of induced HLA-G transcriptional activity following 5-aza-2'-deoxycytidine treatment. Several antigen-presenting machinery components were up-regulated in U251MG cells after demethylating and IFN-γ treatments, suggesting an effect on the up-regulation of HLA-G cell surface expression. Therefore, because of its role in tumor tolerance, HLA-G found to be expressed in glioblastoma samples should be taken into consideration in clinical studies on the pathology and in the design of therapeutic strategies to prevent its expression in HLA-G-negative tumors.
Collapse
Affiliation(s)
- Isabela J Wastowski
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut des Maladies Emergentes et des Thérapies Innovantes, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Zilberman S, Schenowitz C, Agaugué S, Benoît F, Riteau B, Rouzier R, Carosella ED, Rouas-Freiss N, Menier C. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol 2012; 42:1599-608. [PMID: 22678912 DOI: 10.1002/eji.201141761] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Dimers of the nonclassical HLA-G class I molecule have recently been shown to be active structures that mediate inhibition of NK-cell cytotoxic activity through interaction with the immunoglobulin-like transcript (ILT)-2 inhibitory receptor. However, this has only been proven in trophoblasts and HLA-G transfectants. Here, we document for the first time the existence of HLA-G dimers in cancer. Indeed, we identified both surface and soluble HLA-G dimers in tumor cells and malignant ascites respectively. Interestingly, factors from the tumor microenvironment, such as interferons, enhanced the formation of HLA-G dimers and increased the protection of tumors from NK cell-mediated lysis. These data emphasize the impact of HLA-G conformation on its efficiency at inhibiting the antitumor response and thus favoring tumor progression. In view of these results, the effect of the tumor microenvironment on upregulation of HLA-G function deserves particular attention when designing cancer immunotherapy protocols.
Collapse
Affiliation(s)
- Sonia Zilberman
- CEA, IMETI, Service de Recherches en Hemato-Immunologie, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
HoWangYin KY, Loustau M, Wu J, Alegre E, Daouya M, Caumartin J, Sousa S, Horuzsko A, Carosella ED, LeMaoult J. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell Mol Life Sci 2012; 69:4041-9. [PMID: 22802125 DOI: 10.1007/s00018-012-1069-3] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Revised: 05/24/2012] [Accepted: 06/20/2012] [Indexed: 12/29/2022]
Abstract
The non-classical Human leukocyte antigen G (HLA-G) differs from classical HLA class I molecules by its low genetic diversity, a tissue-restricted expression, the existence of seven isoforms, and immuno-inhibitory functions. Most of the known functions of HLA-G concern the membrane-bound HLA-G1 and soluble HLA-G5 isoforms, which present the typical structure of classical HLA class I molecule: a heavy chain of three globular domains α1-α2-α3 non-covalently bound to β-2-microglobulin (B2M) and a peptide. Very little is known of the structural features and functions of other HLA-G isoforms or structural conformations other than B2M-associated HLA-G1 and HLA-G5. In the present work, we studied the capability of all isoforms to form homomultimers, and investigated whether they could bind to, and function through, the known HLA-G receptors LILRB1 and LILRB2. We report that all HLA-G isoforms may form homodimers, demonstrating for the first time the existence of HLA-G4 dimers. We also report that the HLA-G α1-α3 structure, which constitutes the extracellular part of HLA-G2 and HLA-G6, binds the LILRB2 receptor but not LILRB1. This is the first report of a receptor for a truncated HLA-G isoform. Following up on this finding, we show that the α1-α3-Fc structure coated on agarose beads is tolerogenic and capable of prolonging the survival of skin allografts in B6-mice and in a LILRB2-transgenic mouse model. This study is the first proof of concept that truncated HLA-G isoforms could be used as therapeutic agents.
Collapse
Affiliation(s)
- Kiave-Yune HoWangYin
- CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex (MHC) class I molecule that, through interaction with its receptors, exerts important tolerogenic functions. Its main physiological expression occurs in placenta where it seems to participate in the maternal tolerance toward the fetus. HLA-G has been studied as a marker of pregnancy complications such as abortion or pre-eclapmsia. Although HLA-G is not expressed in most adult tissues, its ectopic expression has been observed in some diseases such as viral infections, autoimmune disorders, and especially cancer. HLA-G neo-expression in cancer is associated with the capability of tumor cells to evade the immune control. In this review, we will summarize HLA-G biology and how it participates in these physiopathological processes. Special attention will be paid to its role as a diagnostic tool and also as a therapeutic target.
Collapse
Affiliation(s)
- Alvaro González
- Department of Biochemistry, University Clinic of Navarra, Pamplona, Spain.
| | | | | | | | | | | |
Collapse
|
48
|
Naji A, Menier C, Maki G, Carosella ED, Rouas-Freiss N. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 2012; 26:1889-92. [DOI: 10.1038/leu.2012.62] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
49
|
Fregonezi PA, Silva TG, Simões RT, Moreau P, Carosella ED, Kläy CP, Gonçalves MA, Soares EG, Souto F, Donadi EA, Soares CP. Expression of nonclassical molecule human leukocyte antigen-G in oral lesions. Am J Otolaryngol 2012; 33:193-8. [PMID: 21035918 DOI: 10.1016/j.amjoto.2010.08.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2009] [Revised: 08/05/2010] [Accepted: 08/10/2010] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Human leukocyte antigen (HLA)-G is a nonclassic class I molecule that acts as a modulator of immune responses, and the expression of these molecules in virus-infected cells has been associated with subversion of the immune response. OBJECTIVE In this study, we performed a cross-sectional study, systematically comparing the expression of the HLA-G in benign, premalignant, and malignant oral lesions and correlating it with the presence of high-risk and low-risk human papillomavirus (HPV) types. SPECIMENS AND METHODS: Oral biopsies were collected from 51 patients and analyzed by immunohistochemistry using anti-HLA-G antibody. Human papillomavirus detection and typing from oral biopsies were obtained by polymerase chain reaction using GP5+/GP6+ and specific primers. RESULTS The 51 biopsies were stratified into 3 groups according to lesion grade: oral benign lesions (oral hyperplasia and papilloma, n = 16), oral premalignant lesions (oral leukoplakia with dysplasia and lichen planus, n = 17), and malignant lesions (oral squamous cell carcinoma, n = 18). Human leukocyte antigen-G overexpression was mainly observed in benign and premalignant oral lesions but was not related to HPV infection (P > .05). On the other hand, HPV DNA was detected in 24 (47%) oral lesions, mainly in benign and premalignant lesions, with the most frequent type detected being high-risk HPV type. CONCLUSION The HLA-G molecule was expressed in a significant number of benign oral lesions and was not correlated with HPV infection or oral cancer.
Collapse
|
50
|
Baudhuin J, Lesport E, Sousa S, Migraine J, Vigneron J, Lemaoult J, Carosella ED, Mooney N, Favier B. HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization. Eur J Immunol 2012; 42:700-9. [PMID: 22144141 DOI: 10.1002/eji.201141930] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Revised: 10/14/2011] [Accepted: 11/28/2011] [Indexed: 11/10/2022]
Abstract
HLA-G is a non-classical HLA class I molecule with tolerogenic properties and restricted tissue distribution. The expression of HLA-G can be induced by tumors thus providing an efficient way to escape the anti-tumoral immune response. Although lipid rafts regulate diverse immunological mechanisms their relationship with HLA-G remains controversial. Our results show that HLA-G-mediated inhibition of both the interaction between NK and tumor cells, and of intracellular calcium flux in NK cells conjugated to their target cells were independent of lipid raft integrity. In addition, cytotoxicity assays indicated that HLA-G continued to efficiently inhibit NK-cell cytolytic function in several different tumor cells independently of lipid raft integrity. Confocal microscopy with 3D reconstruction combined with biochemical analysis showed that HLA-G was mainly localized outside the lipid rafts of tumor cells after cross-linking with specific antibody and remained excluded from lipid rafts during interaction with the ILT2 inhibitory receptor of NK cells. This study indicates that the inhibitory function of HLA-G is uncoupled from lipid raft organization, further distinguishing HLA-G from classical HLA molecules and providing novel information in the understanding of tumor immune escape mechanism mediated through HLA-G.
Collapse
Affiliation(s)
- Jeremy Baudhuin
- CEA, I²BM, Service de Recherches en Hemato-Immunologie, F-75475, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|